CN101228172B - 6,7-不饱和-7-氨基甲酰基取代的吗啡喃衍生物 - Google Patents
6,7-不饱和-7-氨基甲酰基取代的吗啡喃衍生物 Download PDFInfo
- Publication number
- CN101228172B CN101228172B CN2006800271187A CN200680027118A CN101228172B CN 101228172 B CN101228172 B CN 101228172B CN 2006800271187 A CN2006800271187 A CN 2006800271187A CN 200680027118 A CN200680027118 A CN 200680027118A CN 101228172 B CN101228172 B CN 101228172B
- Authority
- CN
- China
- Prior art keywords
- compound
- optional
- group
- alkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- INAXVFBXDYWQFN-XHSDSOJGSA-N Morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 195
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 66
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 64
- 239000001257 hydrogen Substances 0.000 claims abstract description 64
- 150000003839 salts Chemical class 0.000 claims abstract description 45
- 239000011780 sodium chloride Substances 0.000 claims abstract description 45
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 40
- 206010047700 Vomiting Diseases 0.000 claims abstract description 33
- 206010010774 Constipation Diseases 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims description 56
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 51
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 43
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 35
- 102000003840 Opioid Receptors Human genes 0.000 claims description 32
- 108090000137 Opioid Receptors Proteins 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 31
- 239000000556 agonist Substances 0.000 claims description 27
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 19
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 17
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 231100000486 side effect Toxicity 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000003851 azoles Chemical class 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 125000003282 alkyl amino group Chemical group 0.000 claims description 11
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 11
- 230000003042 antagnostic Effects 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000005493 quinolyl group Chemical group 0.000 claims description 6
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycontin Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 229960002085 oxycodone Drugs 0.000 claims description 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
- 229960005181 morphine Drugs 0.000 claims description 4
- 229930014694 morphine Natural products 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 14
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 7
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 3
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 2
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims 2
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 abstract description 121
- 125000003342 alkenyl group Chemical group 0.000 abstract description 24
- 125000000304 alkynyl group Chemical group 0.000 abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 abstract description 5
- 206010028813 Nausea Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000003449 preventive Effects 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 230000001225 therapeutic Effects 0.000 abstract 1
- -1 heterocyclic radical Chemical class 0.000 description 66
- 230000035492 administration Effects 0.000 description 51
- 239000002585 base Substances 0.000 description 50
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 28
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 25
- 229910052799 carbon Inorganic materials 0.000 description 25
- 125000000623 heterocyclic group Chemical group 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 239000012453 solvate Substances 0.000 description 24
- 239000002904 solvent Substances 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 125000004414 alkyl thio group Chemical group 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 125000002252 acyl group Chemical group 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 13
- 229940113083 morpholine Drugs 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 210000000813 small intestine Anatomy 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000036526 Transport Rate Effects 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 230000003364 opioid Effects 0.000 description 10
- 210000004556 Brain Anatomy 0.000 description 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 9
- 125000000392 cycloalkenyl group Chemical group 0.000 description 9
- 230000002829 reduced Effects 0.000 description 9
- 206010025482 Malaise Diseases 0.000 description 8
- 125000004423 acyloxy group Chemical group 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 235000021195 test diet Nutrition 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 125000004442 acylamino group Chemical group 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 241000790917 Dioxys <bee> Species 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 150000001350 alkyl halides Chemical class 0.000 description 5
- 125000001118 alkylidene group Chemical group 0.000 description 5
- 238000007112 amidation reaction Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000000428 dust Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- OGGXGZAMXPVRFZ-UHFFFAOYSA-N Cacodylic acid Chemical compound C[As](C)(O)=O OGGXGZAMXPVRFZ-UHFFFAOYSA-N 0.000 description 4
- 241000252983 Caecum Species 0.000 description 4
- 210000004534 Cecum Anatomy 0.000 description 4
- 229920003114 HPC-L Polymers 0.000 description 4
- 210000003405 Ileum Anatomy 0.000 description 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000003810 ethyl acetate extraction Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229920000591 gum Polymers 0.000 description 4
- 239000008079 hexane Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000011812 mixed powder Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 125000002098 pyridazinyl group Chemical group 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000004916 vomit Anatomy 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 3
- 230000000202 analgesic Effects 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000002490 cerebral Effects 0.000 description 3
- 238000006266 etherification reaction Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000005956 isoquinolyl group Chemical group 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 206010058019 Cancer pain Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N Chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- CFBGXYDUODCMNS-UHFFFAOYSA-N Cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 2
- XLMALTXPSGQGBX-GCJKJVERSA-N Dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 2
- RAABOESOVLLHRU-UHFFFAOYSA-N Diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N Diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- 208000000718 Duodenal Ulcer Diseases 0.000 description 2
- 210000003238 Esophagus Anatomy 0.000 description 2
- 208000003243 Intestinal Obstruction Diseases 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N N,N-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 101710008324 RPS24 Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N Tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atoms Chemical group C* 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229910021320 cobalt-lanthanum-strontium oxide Inorganic materials 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- UKPXULFIISGBHG-UHFFFAOYSA-N cyclopropene Chemical compound [CH]1C=C1 UKPXULFIISGBHG-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 108090001120 delta Opioid Receptors Proteins 0.000 description 2
- 229960004193 dextropropoxyphene Drugs 0.000 description 2
- 229910000071 diazene Inorganic materials 0.000 description 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 235000020828 fasting Nutrition 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- JXYZHMPRERWTPM-UHFFFAOYSA-N hydron;morpholine;chloride Chemical compound Cl.C1COCCN1 JXYZHMPRERWTPM-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 230000002475 laxative Effects 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 238000005567 liquid scintillation counting Methods 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000009906 meningitis Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 238000001525 receptor binding assay Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000002769 thiazolinyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 102000037229 δ-opioid receptors Human genes 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N (2Z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 1
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 1
- ASZLNPRMVCGYCI-UHFFFAOYSA-N 1$l^{2}-azolidine Chemical group C1CC[N]C1 ASZLNPRMVCGYCI-UHFFFAOYSA-N 0.000 description 1
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-Dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-Dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- UWKQJZCTQGMHKD-UHFFFAOYSA-N 2,6-Di-tert-butylpyridine Chemical compound CC(C)(C)C1=CC=CC(C(C)(C)C)=N1 UWKQJZCTQGMHKD-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- UMZCLZPXPCNKML-UHFFFAOYSA-N 2H-imidazo[4,5-d][1,3]thiazole Chemical compound C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 description 1
- YHQXBTXEYZIYOV-UHFFFAOYSA-N 3-methylbut-1-ene Chemical group CC(C)C=C YHQXBTXEYZIYOV-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-Toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 210000001015 Abdomen Anatomy 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L Calcium hydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 1
- 229960003178 Choline Chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M Choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N Codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 208000008208 Craniocerebral Trauma Diseases 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N Cyanogen Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- AFFLGGQVNFXPEV-UHFFFAOYSA-N Decene Chemical compound CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- TXCDCPKCNAJMEE-UHFFFAOYSA-N Dibenzofuran Chemical group C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N Dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N Diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N Domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N Droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229960000394 Droperidol Drugs 0.000 description 1
- 206010014599 Encephalitis Diseases 0.000 description 1
- 108010062947 Enkephalin, Ala(2)-MePhe(4)-Gly(5)- Proteins 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 Fentanyl Drugs 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N Glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N Haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 210000001624 Hip Anatomy 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N Hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022000 Influenza Diseases 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N Lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- 229960003406 Levorphanol Drugs 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N Methadone Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 206010028334 Muscle spasms Diseases 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N Nonene Chemical compound CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
- 229960005343 Ondansetron Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 206010034674 Peritonitis Diseases 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Petidina Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N Phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N Prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
- 229940069956 Propoxyphene Drugs 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N Scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 210000000323 Shoulder Joint Anatomy 0.000 description 1
- 229960005077 Sodium Picosulfate Drugs 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N Sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- GOZDTZWAMGHLDY-UHFFFAOYSA-L Sodium picosulfate Chemical compound [Na+].[Na+].C1=CC(OS(=O)(=O)[O-])=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OS([O-])(=O)=O)C=C1 GOZDTZWAMGHLDY-UHFFFAOYSA-L 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N Thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N Thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Tranquisan Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- OVCXRBARSPBVMC-UHFFFAOYSA-N Triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 description 1
- 206010047627 Vitamin deficiency Diseases 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005248 alkyl aryloxy group Chemical group 0.000 description 1
- 125000005157 alkyl carboxy group Chemical group 0.000 description 1
- 230000002152 alkylating Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 201000003126 anuria Diseases 0.000 description 1
- IFNNXDFBUBKSAU-UHFFFAOYSA-L barium(2+);palladium;sulfate Chemical compound [Pd].[Ba+2].[O-]S([O-])(=O)=O IFNNXDFBUBKSAU-UHFFFAOYSA-L 0.000 description 1
- 229910052728 basic metal Inorganic materials 0.000 description 1
- 150000003818 basic metals Chemical class 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- QJBRNNNJBVJKPK-UHFFFAOYSA-N but-1-en-3-yne Chemical group C=[C]C#C QJBRNNNJBVJKPK-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical class N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- ZPWOOKQUDFIEIX-UHFFFAOYSA-N cyclooctyne Chemical compound C1CCCC#CCC1 ZPWOOKQUDFIEIX-UHFFFAOYSA-N 0.000 description 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- YVXHZKKCZYLQOP-UHFFFAOYSA-N hept-1-yne Chemical compound CCCCCC#C YVXHZKKCZYLQOP-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005842 heteroatoms Chemical group 0.000 description 1
- LMYQAZODCDGPSE-UHFFFAOYSA-N hexa-1,2,3,4-tetraene Chemical group [CH2+][C]=C=C=C=C LMYQAZODCDGPSE-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-L lithium;dihydroxide Chemical compound [Li+].[OH-].[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-L 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- MDEQIPCZMDWUEN-UHFFFAOYSA-N methyl 2-(dimethylamino)acetate;hydrochloride Chemical compound Cl.COC(=O)CN(C)C MDEQIPCZMDWUEN-UHFFFAOYSA-N 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 239000002756 mu opiate receptor agonist Substances 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- OSSQSXOTMIGBCF-UHFFFAOYSA-N non-1-yne Chemical group CCCCCCCC#C OSSQSXOTMIGBCF-UHFFFAOYSA-N 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- YBKGERLDRMINOV-UHFFFAOYSA-N oxathiine Chemical compound O1SC=CC=C1 YBKGERLDRMINOV-UHFFFAOYSA-N 0.000 description 1
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- VZCFNJNTQPIJHV-UHFFFAOYSA-N penta-1,2-dien-4-yne Chemical group C=C=[C]C#[C-] VZCFNJNTQPIJHV-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000002980 postoperative Effects 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- OCFVSFVLVRNXFJ-UHFFFAOYSA-N potassium hydride Inorganic materials [H-].[K+] OCFVSFVLVRNXFJ-UHFFFAOYSA-N 0.000 description 1
- 238000009702 powder compression Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- NONQAKWUTFTDMS-UHFFFAOYSA-N prop-2-yn-1-one Chemical group O=[C]C#C NONQAKWUTFTDMS-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000001148 spastic Effects 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000008143 stimulant laxative Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000005886 tetrahydrobenzothienyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000001730 thiiranyl group Chemical group 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QXZGXRIXJAVMTI-UHFFFAOYSA-N tribenzylsilicon Chemical group C=1C=CC=CC=1C[Si](CC=1C=CC=CC=1)CC1=CC=CC=C1 QXZGXRIXJAVMTI-UHFFFAOYSA-N 0.000 description 1
- QXTIBZLKQPJVII-UHFFFAOYSA-N triethylsilicon Chemical group CC[Si](CC)CC QXTIBZLKQPJVII-UHFFFAOYSA-N 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000001757 vomitory Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 102000037275 μ-opioid receptors Human genes 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
用作治疗和/或预防发呕、呕吐和/或便秘的药剂的新型化合物。提供了用式(I)表示的化合物或其药物可接受的盐或溶剂化物:[化学式1]其中R1和R2各自独立地为氢、任选取代的低级烷基、任选取代的低级烯基、任选取代的环烷基、任选取代的芳基等,R3为氢、羟基、任选取代的低级烷基、任选取代的低级烯基、任选取代的低级炔基、任选取代的低级烷氧基等,R4为氢或低级烷基,R5为氢、低级烷基、环烷基低级烷基或低级烯基。
Description
6,7-不饱和-Ί-氨基甲酰基取代的吗啡喃衍生物技术领域[0001] 本发明涉及6,7_不饱和-7-氨基甲酰基取代的吗啡喃衍生物,其用作治疗和/ 或预防恶心、呕吐、呕吐和/或便秘的药剂,尤其用作减轻和/或预防由具有阿片样物质 (opioid)受体(例如阿片样物质μ受体)激动活性的化合物引起的副作用(呕吐、呕吐和 /或便秘等)的药剂。[0002] 阿片样物质受体激动剂如用作止痛药的吗啡等在具有癌症疼痛的患者中非常有效,但作为副作用,引起严重的恶心、发呕(emesis)、呕吐(vomiting)、便秘、无尿和搔痒。 在临床上使用了各种止呕吐剂和抗便秘药,但认为它们中的任何一项都没有表现出足够的效果,仍需要良好的副作用减轻药来提高患者的Q0L。[0003] 专利文献I和2以及非专利文献I大致描述了吗啡喃衍生物能有效治疗或预防阿片样物质μ激动剂引起的发呕和呕吐,非专利文献2描述了 6,7_饱和-7-氨基甲酰基取代的吗啡喃衍生物具有阿片样物质S受体拮抗作用。但是,他们都没有描述或暗示本发明的化合物。[0004][专利文献I]国际专利申请公布W02004-007503[0005][专利文献2]国际专利申请公布W095/13071[0006] [非专利文献 I] Journal of Medicinal Chemistry 41,4177-4180 (1998)[0007] [非专利文献2] Chemical and Pharmaceutical Bulletin, 52 (66) 747-750 (2004)发明内容[0008] 发明解决的问题[0009] 我们发现了能用作治疗和/或预防发呕、呕吐和/或便秘的组合物的6,7_不饱和-7-氨基甲酰基取代的吗啡喃衍生物。[0010] 解决问题的手段[0011] 本发明提供:[0012] (I)用式(I)表示的化合物或其药物可接受的盐或溶剂化物:[0013][化学式I][0014]
[0015] 其中R1和R2各自独立地为氢、任选取代的低级烷基、任选取代的低级烯基、任选取背景技术代的低级炔基、任选取代的低级烷基磺酰基、任选取代的酰基、任选取代的环烷基、任选取代的环烯基、任选取代的芳基、任选取代的杂环基或任选取代的芳基磺酰基,或R1和R2与它们连接的氮原子一起形成任选取代的杂环;
[0016] R3为氢、羟基、任选取代的低级烷基、任选取代的低级烯基、任选取代的低级炔基、任选取代的低级烷氧基、巯基、任选取代的低级烷硫基、任选取代的氨基、任选取代的氨基甲酰基、任选取代的酰基、任选取代的酰氧基、任选取代的芳基或任选取代的杂环基,
[0017] 用下式表示的基团:
[0018][化学式2]
[0021] 其中环A或环B各自独立地为任选取代的含氮杂环,该杂环在环中任选地包含另外的氮原子、氧原子和/或硫原子;
[0022] 虚线代表键的存在或不存在;
[0023] 当虚线代表键的存在时,P为O ;
[0024] 当虚线代表键的不存在时,P为I ;
[0025] Ra为氢、任选取代的低级烷基、任选取代的低级烯基或任选取代的低级炔基;
[0026] 和Rb为氢或氧代;
[0027] R4为氢或低级烷基;
[0028] R5为氢、低级烷基、环烷基低级烷基或低级烯基,(Γ)用式(I)表示的化合物或其药物可接受的盐或溶剂化物:
[0029][化学式3]
[0030]
[0031] 其中R1和R2各自独立地为氢、任选取代的低级烷基、任选取代的低级烯基、任选取代的环烷基、任选取代的芳基或任选取代的杂环基,或
[0032] R1和R2与它们连接的氮原子一起形成任选取代的杂环;
[0033] R3为氢、羟基、任选取代的低级烷基、任选取代的低级烯基、任选取代的低级炔基、任选取代的低级烷氧基、巯基、任选取代的低级烷硫基、任选取代的芳基或任选取代的杂环[0034] R4为氢或低级烷基;[0035] 以及R5为氢、低级烷基、环烷基低级烷基或低级烯基;[0036] (2)根据(I)或(Γ )的化合物或其药物可接受的盐或溶剂化物,其中R3为羟基,[0037] (3)根据(I)或(Γ )的化合物或其药物可接受的盐或溶剂化物,其中R3为任选取代的氨基,[0038] (4)根据(I)或(Γ )的化合物或其药物可接受的盐或溶剂化物,其中R3为被任选取代的芳基磺酰基取代的氨基,[0039] (5)根据(1)-(4)和(Γ)中任何一项的化合物或其药物可接受的盐或溶剂化物, 其中R1为氢或低级烷基,R2为任选取代的低级烷基、任选取代的苯基、任选取代的环烷基或任选取代的杂环基,R5为环丙基甲基;[0040] (6)根据(1)-(5)和(Γ)中任何一项的化合物或其药物可接受的盐或溶剂化物, 其中R1为氢,R2为未被取代的低级烷基;被杂环基取代的低级烷基,该杂环基任选被芳基取代;被低级烧氧基取代的低级烧基;未被取代的苯基;被低级烧基取代的苯基;被低级烧氧基取代的苯基;被低级烧基擬基取代的环烧基;被低级烧氧基取代的杂环基;或被芳基取代的杂环基,R4为氢,R5为环丙基甲基,[0041] (7)包含根据(1)-(6)和(Γ )中任何一项的化合物或其药物可接受的盐或溶剂化物的药物组合物,[0042] (8)包含根据(1)-(6)和(Γ )的化合物或其药物可接受的盐或溶剂化物的具有阿片样物质受体拮抗活性的组合物,[0043] (9)包含根据(1)-(6)和(Γ )中任何一项的化合物或其药物可接受的盐或溶剂化物的用于治疗和/或预防发呕、呕吐和/或便秘的组合物,[0044] (10)包含根据(1)-(6)和(Γ)中任何一项的化合物或其药物可接受的盐或溶剂化物的用于减轻和/或预防由具有阿片样物质受体激动活性的化合物引起的副作用的组合物,[0045] (11)根据(10)的用于治疗和/或预防的组合物,其中副作用为发呕、呕吐和/或便秘,[0046] (12)根据(10)或(11)的用于治疗和/或预防的药剂,其中具有阿片样物质受体激动活性的化合物为吗啡、羟考酮或其药物可接受的盐或溶剂化物,[0047] (13)根据(1)-(6)和(Γ)中任何一项的化合物或其药物可接受的盐或溶剂化物的用途,用于生产治疗和/或预防发呕、呕吐和/或便秘的药物,[0048] (14)根据(1)-(6)和(Γ)中 任何一项的化合物或其药物可接受的盐或溶剂化物的用途,用于生产减轻和/或预防由具有阿片样物质受体激动活性的化合物引起的副作用的药物,[0049] (15)治疗和/或预防发呕、呕吐和/或便秘的方法,包括给药根据(1)-(6)和(Γ) 中任何一项的化合物或其药物可接受的盐或溶剂化物,[0050] (16)减轻和/或预防由具有阿片样物质受体激动活性的化合物引起的副作用的方法,包括给药根据(1)-(6)和(Γ )中任何一项的化合物或其药物可接受的盐或溶剂化物,[0051] (17) 一种止痛剂组合物,包含具有阿片样物质受体激动活性的化合物和有效量的根据(1)_(6)和(Γ)中任何一项的化合物或其药物可接受的盐或溶剂化物,用于减轻和/或预防由于给药具有阿片样物质受体激动活性的化合物引起的副作用,
[0052] (18) 一种止痛剂组合物,包含具有阿片样物质受体激动活性的化合物和有效量的根据(1)_(6)和(Γ)中任何一项的化合物或其药物可接受的盐或溶剂化物,用于治疗和/或预防由于给药具有阿片样物质受体激动活性的化合物引起的发呕、呕吐和/或便秘,
[0053] (19)根据(17)或(18)的止痛剂,其中具有阿片样物质受体激动活性的化合物为吗啡、羟考酮或其药物可接受的盐或溶剂化物。
[0054] 发明效果
[0055] 本发明的化合物⑴具有治疗/或预防发呕、呕吐和/或便秘、尤其是由具有阿片样物质受体(例如阿片样物质μ受体)激动活性的化合物引起的发呕、呕吐和/或便秘的活性,并用作用于减轻已给药或正给药具有阿片样物质受体激动活性的化合物的患者的副作用的组合物。
具体实施方式
[0056]本文使用的“卤素”包括氟、氯、溴和碘。“卤代低级烷基”、“卤代低级烷氧基”和“卤代低级烷硫基”的卤素部分同样如此。
[0057] “低级烷基”包括碳数目为1-10、优选碳数目为1-6、更优选1-3的直链或支链烷基,例子包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戍基、异戍基、新戊基、己基、异己基、正庚基、异庚基、正辛基、异辛基、正壬基和正癸基。优选的为甲基、乙基、异丙基、正丁基、仲丁基、叔丁基和1_乙基丙基。
[0058] “任选取代的低级烷基”的取代基的例子包括齒素、羟基、低级烷氧基、齒代低级烷氧基、羟基低级烷氧基、低级烷硫基、低级烷基氨基、酰基氨基、酰基、酰氧基、氰基、羧基、低级烷氧基羰基、氨基甲酰基、低级烷基氨基甲酰基、氰基氨基甲酰基、低级烷基磺酰基氨基甲酰基、芳基磺酰基氨基甲酰基、氨磺酰基、低级烷基氨磺酰基、低级烷基磺酰基、任选地被选自取代基组α的一个或多个取代基取代的环烷基(其中取代基组α为卤素、羟基、低级烧基、齒代低级烧基、轻基低级烧基、低级烧氧基低级烧基、竣基低级烧基、低级烧氧基擬基低级烧基、氣基低级烧基、低级烧基氣基低级烧基、酸基氣基低级烧基、氛基低级烧基、低级烧氧基、齒代低级烧氧基、轻基低级烧氧基、低级烧硫基、齒代低级烧硫基、酸基、酸氧基、氨基、低级烷基氨基、酰基氨基、氰基、羧基、低级烷氧基羰基、氨基甲酰基、低级烷基氨基甲酰基、芳基氨基甲酰基、氰基氨基甲酰基、低级烷基磺酰基氨基甲酰基、氨磺酰基、低级烷基氨磺酰基、低级烷基磺酰基、任选地被低级亚烷基二氧取代的芳基、和杂环基团)、任选地被选自取代基组α的一个或多个取代基取代的环烯基、任选地被选自取代基组α的一个或多个取代基取代的芳基、任选地被选自取代基组α的一个或多个取代基取代的芳氧基、任选地被选自取代基组α的一个或多个取代基取代的芳硫基、任选地被选自取代基组α的一个或多个取代基取代的杂环基和任选地被选自取代基组α的一个或多个取代基取代的杂环氧基。
[0059] “卤代低级烷基”、“羟基低级烷基”、“氨基低级烷基”、“酰基氨基低级烷基”、“酰氧基低级烷基”、“环烷基低级烷基”、“低级烷氧基”、“卤代低级烷氧基”、“羟基低级烷氧基”、“低级烧氧基低级烧基”、“低级烧氧基擬基”、“竣基低级烧基”、“低级烧氧基擬基低级烧基”、 “低级烧硫基”、“齒代低级烧硫基”、“低级烧基氣基”、“低级烧基氣基低级烧基”、“低级烧基氨基甲酰基”、“低级烷基氨磺酰基”、“低级烷基磺酰基”、“芳基低级烷基”、“三低级烷基甲硅烷基”、“低级烷基二芳基甲硅烷基”、“三芳基低级烷基甲硅烷基”、“低级烷氧基低级烷氧基低级烷基”、“低级烷硫基低级烷基”、“芳基低级烷氧基低级烷基”、“低级烷基磺酰基”、“低级烷基磺酰基氨基甲酰基”、“低级烷基羰基”、“氰基低级烷基”、“低级烷氧基羰基氨基”、“低级亚烷基二氧基”和“杂环低级烷基”中的低级烷基部分与前面提到的“低级烷基”相同。[0060] “任选取代的低级烷氧基”、“任选取代的低级烷硫基”和“任选取代的低级烷基磺酰基”的取代基与前面提到的“任选取代的低级烷基”的取代基相同。[0061] “低级烯基”包括碳数目为2-10、优选碳数目为2-8、更优选碳数目为3-6的在任意位置具有一个或多个双键的直链或支链烯基。具体地,例子包括乙烯基、烯丙基、丙烯基、 异丙稀基、丁稀基、异丁稀基、含异戍~■稀基的、丁~■稀基、戍稀基、异戍稀基、戍~■稀基、己稀基、异己稀基、己_■稀基、庚稀基、羊稀基、壬稀基和癸稀基。R5中的低级稀基优选为稀丙基。[0062] “任选取代的低级烯基”的取代基与“任选取代的低级烷基”的取代基相同。[0063] “低级炔基”包括碳数目为2-10、优选碳数目为2-8、更优选碳数目为3_6的在任意位置具有一个或多个三键的直链或支链炔基。具体地,例子包括乙炔基、丙炔基、丁炔基、戊炔基、己炔基、庚炔基、辛炔基、壬炔基和癸炔基。它们还可在任意位置具有双键。[0064] “任选取代的低级炔基”的取代基与“任选取代的低级烷基”的取代基相同。[0065] “任选取代的氨基”的取代基的例子包括任选地被选自取代基组α的一个或多个取代基取代的低级烷基、任选地被选自取代基组α的一个或多个取代基取代的环烷基、任选地被选自取代基组α的一个或多个取代基取代的酰基、任选地被选自取代基组α的一个或多个取代基取代的氨基、任·选地被选自取代基组α的一个或多个取代基取代的芳基、 氨磺酰基、任选地被选自取代基组α的一个或多个取代基取代的低级烷基氨磺酰基、任选地被选自取代基组α的一个或多个取代基取代的芳基氨磺酰基、任选地被选自取代基组 α的一个或多个取代基取代的低级烧基磺酰基、任选地被选自取代基组α的一个或多个取代基取代的芳基磺酰基、任选地被选自取代基组α的一个或多个取代基取代的芳基氨基和任选地被选自取代基组α的一个或多个取代基取代的杂环基。[0066] “任选取代的氨基甲酰基”的取代基与“任选取代的氨基”的取代基相同。[0067] “环烷基”为碳数目为3-10、优选碳数目为3-8、更优选碳数目为4_8的碳环基团, 例如,包括环丙基、环丁基、环戊基、环己基、环庚基、环辛基、环壬基和环癸基。它们还可在任意位置与后文描述的“芳基”或后文描述的“杂环基”稠合。[0068] 对于R1和R2中的“环烷基”,环丙基、环丁基、环戊基和环己基是优选的。[0069] “环烷基低级烷基”和“环烷基羰基”的环烷基部分与前面提到的“环烷基”相同。[0070] 对于R5中的“环烷基低级烷基”,环丙基甲基是优选的。[0071] “任选取代的环烷基”的取代基的例子包括选自上述取代基组α的一个或多个取代基。取代基可在任意位置处取代,并可在具有环烷基键的碳原子处取代。[0072] “环烯基”包括在上述环烷基的环中在任意位置处具有一个或多个双键的环烯基, 例子包括环丙烯基、环丁烯基、环戊烯基、环己烯基、环庚烯基、环辛炔基和环己二烯基。[0073] 对于R1或R2中的“环烯基”,环丙烯基、环丁烯基、环戊烯基和环己烯基是优选的。
[0074] “环烯基羰基”的环烯基部分与前面提到的“环烯基”相同。
[0075] “任选取代的环烯基”的取代基与上述“任选取代的环烷基”的取代基相同。
[0076] “芳基”包括苯基、萘基、蒽基和菲基,苯基是尤其优选的。
[0077] “芳氧基”、“芳硫基”、“芳基低级烷基”、“低级烷基二芳基甲硅烷基”、“三芳基低级烷基甲硅烷基”、“芳基低级烷氧基低级烷基”、“芳基磺酰基”、“芳基氨磺酰基(sofamoyl) ”、“芳基氨基”、“芳基氨基甲酰基”和“芳基磺酰基氨基甲酰基”的芳基部分与上述“芳基”相同。
[0078] “任选取代的芳基”、“任选取代的苯基”和“任选取代的芳基磺酰基”的取代基的例子包括取代基组α、被选自取代基组α的一个或多个基团取代的苯基、被选自取代基组α的一个或多个基团取代的苯氧基和低级亚烧基~■氧基。
[0079] “杂环基”包括在环中具有任意选自O、S和N的一个或多个杂原子的杂环基,具体包括5-至6-元杂芳基,如吡咯基、咪唑基、吡唑基、吡啶基、哒嗪基、嘧啶基、吡嗪基、三唑基、三嗪基、四唑基、异卩恶唑基、〖恶唑基J恶二唑基、异噻唑基、噻唑基、噻二唑基、呋喃基和唾吩基;双环桐合杂环基,如喷噪基、异Π引噪基、Π引卩坐基、Π引噪烧基(indoIidinyI)、二氢吲哚基、异二氢吲哚基、喹啉基、异喹啉基、噌啉基、酞嗪基、喹唑啉基、萘啶基(naphthridinyl)、喹喔啉基、嘌呤基、蝶啶基、苯并呲喃基、苯并咪唑基、苯并异〖恶唑基、苯并恶唑基、苯并恶二唑基、苯并异噻唑基、苯并噻唑基、苯并噻二唑基、苯并呋喃基、异苯并呋喃基、苯并噻吩基、苯并三唑基、咪唑 并吡啶基、三唑并吡啶基、咪唑并噻唑基、吡嗪并哒嗪基、喹唑啉基、喹啉基、异喹啉基、萘啶基、二氢吡啶基、四氢喹啉基和四氢苯并噻吩基;三环稠合杂环基,如咔唑基、吖啶基、咕吨基、吩噻嗪基、苯氧硫杂环己二烯基(phenoxathiinyl)、吩卩恶嗪基和二苯并呋喃基;非芳香杂环基,如二氧杂环己烧基、硫杂丙环基、thioranyl、thietanyl、oxi Ianyl、氧杂环丁基、oxathioranyl、口丫丁 P定基、thianyl、吡咯烷基、吡咯啉基、咪唑烷基、咪唑啉基、吡唑烷基、吡唑啉基、哌啶基、哌嗪基、吗啉基、吗啉代、硫代吗啉基、硫代吗啉代、二氢吡啶基、二氢呋喃基、四氢呋喃基、四氢吡喃基、四氢噻唑基和四氢异噻唑基。优选的为5-至6-元杂芳基或非芳香杂环基。
[0080] 对于R1和R2中的“杂环基”,吡唑基、批啶基、哒嗪基、嘧啶基、吡嗪基、异囉唑基、噻唑基、噻二唑基、呋喃基、噻吩基、吲哚基、吲唑基、喹啉基、异喹啉基、苯并〖恶唑基、苯并噻唑基、氧杂环丁基、四氢呋喃基和四氢吡喃基是优选的。吡啶基、哒嗪基、嘧啶基和吡嗪基是更优选的。吡啶基和嘧啶基是尤其优选的。
[0081] 对于R1和R2中的“任选取代的低级烷基”中的杂环基,异囉唑基、囉唑基和囉二唑基是优选的。二唑基是尤其优选的。
[0082] “杂环氧基”和“杂环低级烷基”的杂环部分与上述“杂环基”相同。
[0083] “任选取代的杂环基”的取代基的例子包括选自取代基组α和氧代组成的组中的一个或多个基团。取代基可在任意位置处取代,或可在具有杂环基键的碳原子或氮原子处取代。
[0084] “酰基”包括碳数目为1-10、优选碳数目1-6、更优选碳数目1-4的直链或支链类脂族酰基,碳数目为4-9、优选碳数目4-7的环状脂族酰基,芳酰基和杂环羰基。这里,“链类脂族”包括上述“低级烷基”、上述“低级烯基”和上述“低级炔基”。“环脂族”包括上述“环烷基”和上述“环烯基”。杂环羰基的杂环部分与上述“杂环基”相同。酰基的例子包括甲酰基、乙酰基、丙酰基、丁酰基、异丁酰基、戊酰基、新戊酰基、己酰基、丙烯酰基、丙炔酰基、甲基丙烯酰基、丁烯酰基、环丙基羰基、环己基羰基、环辛基羰基、苯甲酰基、吡啶羰基、哌啶羰基、喊嚷擬基、吗琳擬基等。[0085] “酰氧基”、“酰基氨基”、“酰基氨基低级烷基”和“酰氧基低级烷基”的酰基部分与上述“酰基”相同。[0086] 当“酰基”为链类脂族酰基时,“任选取代的酰基”或“任选取代的”的取代基与上述“任选取代的低级烷基”的取代基相同,当“酰基”为环脂族酰基、芳酰基或杂环羰基时, 包括选自取代基组α中的一个或多个基团。[0087] R1和R2与它们连接的氮原子共同形成的“任选取代的杂环”包括包含连接到R1和 R2上的氮原子的5-元或6-元杂环,而且,任选地包含选自N、S和O的一个或多个杂原子。 例如,包括以下时的情况,[0088][化学式4][0089]
[0090] 为饱和杂环基,如[0091]
[0092] 或不饱和杂环基,如[0093]
[0094] 其中,R6、R7和R8各自独立地为氢、卤素、羟基、低级烷基、低级烷氧基、低级烷硫基、酸基、酸氧基、氣基、低级烧基氣基、酸基氣基、低级烧氧基擬基氣基、竣基或低级烧氧基羰基,并且优选饱和杂环基,如任选地被氢、卤素、羟基或低级烷基取代的吗啉环、吡咯烷环、哌啶环、哌嗪环等。
[0095] “R1和R2与它们连接的氮原子共同形成的任选取代的杂环”的取代基与“任选取代的杂环基”的取代基相同。
[0096][化学式5] [0097]
为
[0098] 或
[0099] 包括例如下面这些:
[0100][化学式6]
[0101]
[0102] 其中Ra如上面所定义,R为氢或选自取代基组α中的基团。[0103] 本文中,“溶剂化物”包括例如与有机溶剂的溶剂化物、水合物等。当形成水合物时,可配合任意数量的水分子。[0104] 化合物(I)包括药物可接受的盐。例子包括与碱金属(锂、钠或钾)的盐、与碱土金属(镁或钙)的盐、与铵的盐、与有机碱或氨基酸的盐,和与无机酸(盐酸、硫酸、硝酸、氢溴酸、磷酸和氢碘酸)或有机酸(乙酸、三氟乙酸、柠檬酸、乳酸、酒石酸、草酸、马来酸、富马酸、扁桃酸、戊二酸、苹果酸、苯甲酸、邻苯二甲酸、苯磺酸、对-甲苯磺酸、甲磺酸或乙磺酸) 的盐。特别地,盐酸、磷酸、酒石酸或甲磺酸是优选的。可通过常规方法形成这些盐。[0105] 另外,化合物(I)不限于特定的异构体,而是包括所有可能的异构体和外消旋物。 例如,当化合物(I)的R3为羟基时,化合物(I)包括其它互变异构体,即下面的化合物(I’)。[0106][化学式7]
[0107]
[0108] 可通过下面的方法生产本发明的化合物(I)。
[0109] (A 方法)
[0110][化学式S]
[0111]
[0112] 其中Ra为酯残基,Rb为氢或羟基保护基团,其它符号如上面所定义。
[0113] 这里,酷残基包括低级烧基如甲基、乙基等,芳基低级烧基如节基、苯乙基等,酸氧基低级烷基如乙酰氧基甲基等。
[0114] 羟基保护基团不限于但包括低级烷基(甲基、叔丁基等)、芳基低级烷基(三苯基甲基、苄基等)、三低级烷基甲硅烷基(三甲基甲硅烷基、叔丁基二甲基甲硅烷基、三乙基甲硅烷基、三异丙基甲硅烷基等)、低级烷基二芳基甲硅烷基(叔丁基二苯基甲硅烷基等)、三芳基低级烷基甲硅烷基(三苄基甲硅烷基等)、低级烷氧基低级烷基(甲氧基甲基、1-乙氧基乙基、1-甲基-1-甲氧基乙基等)、低级烷氧基低级烷氧基低级烷基(甲氧基乙氧基甲基等)、低级烷硫基低级烷基(甲硫基甲基等)、任选取代的四氢吡喃基(四氢吡喃-2-基、4_甲氧基四氢吡喃-4-基等)、四氢硫代吡喃基(四氢硫代吡喃-2-基等)、四氢呋喃基(四氢呋喃-2-基等)、四氢硫代呋喃基(四氢硫代呋喃-2-基等)、芳基低级烷氧基低级烷基(苄氧基甲基等)、低级烷基磺酰基(甲磺酰基、乙磺酰基等)、酰基(乙酰基等)和芳基磺酰基(对甲苯磺酰基等)。
[0115](第一个步骤)
[0116] 首先,通过常规方法对已知的化合物或由其衍生的化合物(IV)去保护。
[0117] 例如,当保护基团为苄基时,将化合物溶解或悬浮在合适的溶剂(乙酸乙酯、甲醇、乙醇、四氢呋喃、二氧杂环己烷、二甲基甲酰胺、乙酸、稀盐酸或它们的混合物)中,使用钯催化剂(氢氧化钯、钯-碳、钯-硫酸钡、钯-氧化铝、钯黑等)的氢化反应提供化合物(III)。可在约0°C -约100°C、优选约20°C -约50°C下进行反应约15分钟至约24小时、(V) (Ib)[0126] 其中R3a为羟基或任选取代的低级烷氧基,其它符号如上面所定义。[0127](第一个步骤)[0128] 当目标化合物(I)的R3为任选取代的低级烷氧基时,首先,通过常规方法醚化已知的化合物(IV)。[0129] 例如,在碱(氢化钠、氢化钾、氢氧化钠、氢氧化钾、氢氧化钙、氢氧化钡、碳酸钠、 碳酸钾、碳酸钙、碳酸铯、甲醇钠、乙醇钠、叔丁醇钾、碳酸氢钠或金属钠)存在时或在合适优选约I小时至约5小时。[0118](第二个步骤)[0119] 然后,直接酰胺化得到的化合物(III)以得到化合物(la)。[0120] 例如,可通过在合适溶剂(甲醇、乙醇、四氢呋喃、二甲基甲酰胺、二乙醚、二氯甲烧、二氯乙烷、甲苯、二甲苯、氯苯、邻二氯苯、2-甲氧基乙醇或二甘醇二甲醚或它们的混合物)中或没有溶剂时在有或没有胺化合物(氨、二甲胺、三乙胺、吡啶、二甲基苯胺、二甲基氨基吡啶、二甲基吡啶等)的情况下在约0°C -约250°C、优选约80°C -约200°C下加热约 30分钟到约24小时、优选约1-12小时来使化合物(III)和化合物(II)反应。[0121] 为了有效推进反应,可通过微波照射进行反应。对反应温度和照射时间没有特殊限制,但为约100°C到约200°C和约5分钟到约5小时,优选约10分钟到约I小时。作为溶剂,优选使用极性溶剂,如甲醇、乙醇、1-丙醇、乙二醇、甘油、2-甲氧基乙醇、2-乙氧基乙醇、N,N-二甲基甲酰胺、二甘醇二甲醚等。[0122] 当目标化合物(I)的R4为低级烷基时,可通过在任意阶段的常规醚化反应得到目标化合物。[0123] (B 方法)[0124][化学式9][0125]
的溶剂(N,N-二甲基甲酰胺、二甲基亚砜、甲苯、苯、二甲苯、它们的混合物等)环己烷、己烷、二氯甲烷、1,2_ 二氯乙烷、四氢呋喃、二氧杂环己烷、丙酮、甲基乙基酮、乙腈、水或它们的混合物)中在Mitsunobu反应条件下使化合物与烧基化试剂或对应于目标化合物的具有R3a基团的醇反应得到化合物(VII)。可在-70至180°C优选约0-150°C下进行反应约15分钟到约24小时,优选约I小时到约5小时。
[0130](第二个步骤)
[0131] 然后,水解化合物(VII)得到化合物(VI)。可使用无机碱(氢氧化钠、氢氧化锂或氢氧化钾)在合适溶剂(甲醇、乙醇、四氢呋喃、二氧杂环己烷、二甲基甲酰胺或它们的混合物)中在冰冷至溶剂的回流温度下进行反应约15分钟到约24小时,优选I小时到约5小时。
[0132](第三个步骤和第四个步骤)
[0133] 然后,酰胺化化合物(VI),对得到的化合物(V)去保护以得到目标化合物(lb)。可通过分别与A方法中第二个步骤和第一个步骤的方法相同的方法进行这些反应。在酰胺化步骤中,如果需要,可在缩合剂(N,N’ - 二环己基碳二亚胺、N-二甲基氨基丙基-N’ -乙基碳二亚胺、二乙基磷酰氰、二苯基磷酰叠氮等)存在下进行反应。
[0134] 另外,在目标化合物(I)的R4为低级烷基时,可在上面所述的任意阶段进行醚化反应。
[0135] (C 方法)
[0136][化学式 10]
[0137]
[0138] 其中L为离去基团,R3b为氢、任选取代的低级烷基、任选取代的低级烯基、任选取代的低级炔基、任选取代的低级烷氧基、巯基、任选取代的低级烷硫基、任选取代的氨基、任选取代的氨基甲酰基、任选取代的芳基或任选取代的杂环基,其它符号如上面所定义。
[0139](第一个步骤)
[0140]当目标化合物⑴的R3为R3b时,将离去基团L(例如三氟甲磺酰基、甲磺酰基、磷酸酯等)引入到已知的化合物(IV)中。例如,在碱(吡啶、三乙胺、氨、二甲胺、二甲基苯胺、二甲基氨基吡啶、2,6- 二甲基吡啶或2,6- 二叔丁基吡啶)存在时使用二氯甲烷、氯仿、四氢呋喃、苯、甲苯、二甲基甲酰胺、乙酸乙酯或它们的混合物作为溶剂使化合物与三氟甲磺酸酐、三氟甲磺酰基氯、甲磺酰基氯、甲磺酸酐、对甲苯磺酰基氯、N-苯基三氟甲磺酰亚胺或各种磷酸酯化试剂反应。[0141](第二个步骤)[0142] 使这样得到的化合物(VIII)进行已知的取代基引入反应以得到化合物(IX)。[0143](第三个步骤、第四个步骤和第五个步骤)[0144] 分别按与B方法中的第二个步骤、A方法中的第二个步骤和A步骤中的第一个步骤相同的方法对化合物(IX)水解、酰胺化和去保护,得到目标化合物(1C)。[0145] 另外,当目标化合物(I)的R4为低级烷基时,可在如上所述的任意阶段进行醚化反应。[0146] (D 方法)[0147] 通过C方法中的第一个步骤得到化合物(VIII),根据C方法中的第四个步骤的方法酰胺化,并分别按照C方法中第二个步骤、第三个步骤和第五个步骤的方法进行引入取代基R3b、去保护和水解反应,从而还得到目标化合物(I)。[0148] 所有这样得到的本发明的化合物都具有阿片样物质受体拮抗活性,并可用作药物,在用式(I)表示的化合物中,下面的化合物是尤其优选的。[0149] a)#为氢或低级烷基的化合物,[0150] WR1为氢或C1-C3烷基的化合物,[0151] c) R2为以下的 化合物:[0152] (c-1)任选地被选自取代基组β的一个或多个基团取代的低级烷基(这里,取代基组β为任选地被羟基取代的环烷基、卤素、羟基、低级烷氧基、卤代低级烷氧基、低级烷硫基、氣基、低级烧基氣基、竣基、低级烧氧基擬基、氰1基、低级烧基横酸基、芳基、芳氧基和低级亚烷基二氧),[0153] (c-1i)任选地被选自取代基组β、低级烷基和卤代低级烷基中的一个或多个基团取代的苯基,[0154] (c-1ii)任选地被选自取代基组β的一个或多个基团取代的芳基低级烷基,[0155] (c-1v)任选地被选自取代基组β的一个或多个基团取代的环烷基,[0156] (c-v)任选地被选自取代基组β的一个或多个基团取代的杂环基,或[0157] (c-vi)任选地被选自取代基组β的一个或多个基团取代的杂环低级烷基,[0158] d)其中R2为以下基团的化合物:[0159] (d-1)任选地被羟基取代的低级烷基,任选地被羟基取代的环烷基,低级烷氧基, 低级烧硫基,低级烧基氣基或芳氧基,[0160] (d-1i)任选地被卤素、低级烷基、卤代低级烷基、低级烷氧基、卤代低级烷氧基、低级烧硫基、氣基、低级烧基氣基、氛基、低级烧基横酸基或低级亚烧基_■氧取代的苯基,[0161] (d-1ii)任选地被低级烷氧基或低级烷硫基取代的芳基低级烷基,[0162] (d-1v)任选地被低级烷基、羧基或低级烷氧基羰基取代的环烷基,[0163] (d-v)任选地被低级烷基、低级烷氧基或苯基取代的杂环基,或[0164] (d-vi)任选地被低级烷基或芳基取代的杂环低级烷基,[0165] e)^和R2与它们结合的N原子共同形成5元或6元饱和杂环的化合物,[0166] f) R3为羟基或低级烷氧基的化合物,
[0167] g) R3为羟基的化合物,
[0168] h) R3为任选地被选自取代基组α中的一个或多个基团取代的氨基的化合物,
[0169] i) R3为卤素、低级烷基或被用低级烷氧基任选取代的芳基磺酰基取代的氨基的化合物,
[0170] j) R4为氢或甲氧基的化合物,
[0171] k)R5为环烷基低级烷基或低级烯基的化合物,
[0172] DR5为环丙基甲基或烯丙基的化合物,
[0173] m)R5为环丙基甲基的化合物,
[0174] n) R1为氢或低级烧基、R2为(d-1)、R3为轻基或低级烧氧基、R4为氢和R5为环烧基低级烷基或低级烯基的化合物,
[0175] ο) R1为氢或低级烧基、R2为(d-1)、R3为轻基或低级烧氧基、R4为氢和R5为环丙基甲基的化合物,
[0176] P)!?1为氢或低级烧基、R2为(d-1)、R3为卤素、低级烧基或被用低级烧氧基任选取代的芳基磺酰基取代的氨基、R4为氢和R5为环烷基低级烷基或低级烯基的化合物,
[0177] q) R1为氢或低级烧基、R2为(d-1)、R3为卤素、低级烧基或被用低级烧氧基任选取代的芳基磺酰基取代的 氨基、R4为氢和R5为环丙基甲基的化合物,
[0178] r) R1为氢或低级烧基、R2为(d_ii)、R3为轻基或低级烧氧基、R4为氢和R5为环烧基低级烷基或低级烯基的化合物,
[0179] s)!?1为氢或低级烧基、R2为(d-1i)、R3为轻基或低级烧氧基、R4为氢和R5为环丙基甲基的化合物,
[0180] t)RJ为氢或低级烧基、R2为(d-1ii)、R3为轻基或低级烧氧基、R4为氢和R5为环烧基低级烷基或低级烯基的化合物,
[0181] u)R1为氢或低级烧基、R2为(d-1ii)、R3为轻基或低级烧氧基、R4为氢和R5为环丙基甲基的化合物,
[0182] v) R1为氢或低级烧基、R2为(d-1V)、R3为轻基或低级烧氧基、R4为氢和R5为环烧基低级烷基或低级烯基的化合物,
[0183] w) R1为氢或低级烧基、R2为(d-1V)、R3为轻基或低级烧氧基、R4为氢和R5为环丙基甲基的化合物,
[0184] x) R1为氢或低级烧基、R2为(d-v)、R3为轻基或低级烧氧基、R4为氢和R5为环烧基低级烷基或低级烯基的化合物,
[0185] y) R1为氢或低级烧基、R2为(d-v)、R3为轻基或低级烧氧基、R4为氢和R5为环丙基甲基的化合物,
[0186] z)RJ为氢或低级烧基、R2为(d-vi)、R3为轻基或低级烧氧基、R4为氢和R5为环烧基低级烷基或低级烯基的化合物,
[0187] aa) R1为氢或低级烧基、R2为(d_vi)、R3为轻基或低级烧氧基、R4为氢和R5为环丙基甲基的化合物,
[0188] aWR1和R2与它们结合的N原子共同形成5元或6元饱和杂环、R3为羟基或低级烷氧基、R4为氢和R5为环烷基低级烷基或低级烯基的化合物,[0189] aWR1和R2与它们结合的N原子共同形成5元或6元饱和杂环、R3为羟基或低级烷氧基、R4为氢和R5为环丙基甲基的化合物,[0190] 或它们的药物可接受的盐或溶剂化物。[0191] 在用式⑴表示的化合物中,R4为氢、R5为环丙基甲基以及NR1R2和R3的组合 (NR1R2, R3)的化合物如下。[0192][表 I][0193]
[0194]
〔0199—)0199 表30200
[0202][表 4]
[0203]
[0205] [表 5]
[0206]
[0207]
[0208][表 6]
[0209]
[0211] 在上面的表中,用下面的符号表示CR9CR'[0212][表 7][0213]
[0214]
[0215]
[0216] [表 8]
[0217]
[0218]
[0219]
OV
‘ ΟΛ iAV) ‘ (9Λ iAV) ‘ (VA iAV) ‘(31 ‘XV) ‘ (91 ‘XV) ‘ (VI ‘XV) ‘ (ΖΛ ‘XV) ‘ (ΑΛ ‘XV) [Ζ,οεο]
‘ (ΧΛ ‘XV) ‘ (Μ ‘XV) ‘ (ΛΛ ‘XV) ‘ (ΠΛ ‘XV) ‘ (ΧΛ ‘XV) ‘ (SA ‘XV) ‘ (Μ ‘XV) ‘ (GA ‘XV) [9000]
‘ (dA ‘XV) ‘ (0Λ ‘XV) ‘ (NA ‘XV) ‘ (嫩 ‘XV) ‘(ΊΛ ‘XV) ‘ (M ‘XV) ‘ (ΓΛ ‘XV) ‘ (ΙΛ ‘XV) [9000]
‘ (ΗΛ ‘XV) ‘ (0Λ ‘XV) ‘ (ΗΛ ‘XV) ‘ (3Λ ‘XV) ‘ (0Λ ‘XV) ‘ (3Λ ‘XV) ‘ (9Λ ‘XV) ‘ (VA ‘XV) [1^000]
‘ Ol ‘IV) ‘ (91 ‘IV) ‘ (VI ‘IV) ‘ (ΖΛ ‘IV) ‘ (ΑΛ ‘IV) ‘ (ΧΛ ‘IV) ‘ (M ‘IV) ‘ (ΛΛ ‘鮮)[εοεο]
‘ (ΠΛ iIV) ‘ CLA iIV) ‘ (SA iIV) ‘ (M iMV) ‘ (GA iMV) ‘ (dA iMV) ‘ (0Λ iMV) ‘ (NA iMV) [2000]
‘(嫩 iMV) ‘(ΊΛ iMV) ‘ (M iMV) ‘ (ΓΛ iMV) ‘ (ΙΛ iMV) ‘ (ΗΛ iMV) ‘ (0Λ iMV) ‘ (ΗΛ iMV) [1000]
‘ (3Λ iMV) ‘ (0Λ iMV) ‘ (DA ‘IV) ‘ (9Λ iMV) ‘ (VA ‘IV) ‘ (DM iAV) ‘ (91 iAV) ‘ (VM iAV) [0000]
‘ (ΖΛ iAV) ‘ (AA iAV) ‘ (ΧΛ iAV) ‘ (MA iAV) ‘ (ΛΛ iAV) ‘ (ΠΛ iAV) ‘ (ΧΛ iAV) ‘ (SA iAV) [6620]
‘ (Μ iAV) ‘ (GA iAV) ‘ (dA iAV) ‘ (0Λ iAV) ‘ (NA iAV) ‘ (嫩 iAV) ‘(ΊΛ iAV) ‘ (M iAV) [8620]
‘ (ΓΛ iAV) ‘ (ΙΛ iAV) ‘ (ΗΛ iAV) ‘ (0Λ iAV) ‘ (ΗΛ iAV) ‘ (3Λ iAV) ‘ (0Λ iAV) ‘ (DA iAV) [Z.620]
‘ (9Λ iAV) ‘ (VA iAV) ‘ (DM iHV) ‘ (91 iHV) ‘ (VM iHV) ‘ (ΖΛ iHV) ‘ (AA iHV) ‘ (ΧΛ iHV) [9620]
‘ (MA iClV) ‘ (ΛΛ iClV) ‘ (ΠΛ iHV) ‘ (ΧΛ iHV) ‘ (SA iHV) ‘ (M iHV) ‘ (GA iHV) ‘ (dA iHV) [9620]
‘ (0Λ iClV) ‘ (NA iClV) ‘ (嫩 iClV) ‘ (ΊΛ iHV) ‘ (M iHV) ‘ (ΓΛ iHV) ‘ (ΙΛ iHV) ‘ (ΗΛ iHV)[饨20]
‘ (0Λ iClV) ‘ (ΗΛ iClV) ‘ (3Λ iHV) ‘ (0Λ iHV) ‘ (DA iHV) ‘ (9Λ iHV) ‘ (VA iHV) ‘ (DM iIV) [0620]
‘ (91 iXV) ‘ (VM iIV) ‘ (ΖΛ iXV) ‘ (AA iIV) ‘ (ΧΛ iXV) ‘ (MA iIV) ‘ (ΛΛ iXV) ‘ (ΠΛ iXV) [2620]
‘ CLA iIV) ‘ (SA iIV) ‘ (M iXV) ‘ (GA iXV) ‘ (dA iXV) ‘ (0Λ iXV) ‘ (NA iXV) ‘ (嫩 iXV) [1620]
‘ (ΊΛ iXV) ‘ (M iXV) ‘ (ΓΛ iXV) ‘ (ΙΛ iXV) ‘ (ΗΛ iXV) ‘ (0Λ iXV) ‘ (ΗΛ iXV) ‘ (3Λ iXV) [0620]
‘ (0Λ iXV) ‘ (DA iIV) ‘ (9Λ iXV) ‘ (VA iIV) ‘ (DM iSV) ‘ (91 iSV) ‘ (VM iSV) ‘ (ΖΛ iSV) [6820]
‘ (AA iSV) ‘ (ΧΛ iSV) ‘ (MA iSV) ‘ (ΛΛ iSV) ‘ (ΠΛ iSV) ‘ (ΧΛ iSV) ‘ (SA iSV) ‘ (M iSV) [8820]
‘ (GA iSV) ‘ (dA iSV) ‘ (0Λ iSV) ‘ (NA iSV) ‘ (ΜΛ iSV) ‘(ΊΛ iSV) ‘ (M iSV) ‘ (ΓΛ iSV) [Z.820]
‘ (ΙΛ iSV) ‘ (ΗΛ iSV) ‘ (0Λ iSV) ‘ (ΗΛ iSV) ‘ (3Λ iSV) ‘ (0Λ iSV) ‘ (DA iSV) ‘ (9Λ iSV) [9820]
‘ (VA iSV) ‘ (DM iW) ‘ (91 iHV) ‘ (VM iW) ‘ (ΖΛ iHV) ‘ (AA iW) ‘ (ΧΛ iHV) ‘ (MA iW) [9820]
‘ (ΛΛ iHV) ‘ (ΠΛ iHV) ‘ CLA iW) ‘ (SA iW) ‘ (M iHV) ‘ (GA iHV) ‘ (dA iHV) ‘ (0Λ iHV)[饨20]
‘ (NA iHV) ‘ (嫩 iHV) ‘(ΊΛ iHV) ‘ (M iHV) ‘ (ΓΛ iHV) ‘ (ΙΛ iHV) ‘ (ΗΛ iHV) ‘ (0Λ iHV) [0820]
‘ (ΗΛ iHV) ‘ (3Λ iHV) ‘ (0Λ iHV) ‘ (DA iW) ‘ (9Λ iHV) ‘ (VA iW) ‘ (DM iQV) ‘ (91 iQV) [2820]
‘ (VM iQV) ‘ (ΖΛ iQV) ‘ (AA iQV) ‘ (ΧΛ iQV) ‘ (MA iQV) ‘ (ΛΛ iQV) ‘ (ΠΛ iQV) ‘ (ΧΛ iQV) [1820]
‘ (SA iQV) ‘ (Μ iQV) ‘ (QA iQV) ‘ (dA iQV) ‘ (0Λ iQV) ‘ (NA iQV) ‘ (M iQV) ‘(ΊΛ iQV) [0820]
‘ (M iQV) ‘ (ΓΛ iQV) ‘ (ΙΛ iQV) ‘ (ΗΛ iQV) ‘ (0Λ iQV) ‘ (AA iQV) ‘ (3A iQV) ‘ (0Λ iQV) [6Z.20]
‘ (DA iQV) ‘ (9Λ iQV) ‘ (VA iQV) ‘ (DM MV) ‘ (91 MV) ‘ (VM MV) ‘ (ΖΛ MV) ‘ (AA MV) [8Z.20]
‘ (ΧΛ MV) ‘ (MA MV) ‘ (ΛΛ MV) ‘ (ΠΛ MV) ‘ (ΧΛ MV) ‘ (SA MV) ‘ (M MV) ‘ (GA MV) [LLZO]
‘ (dA MV) ‘ (0Λ MV) ‘ (NA MV) ‘ (嫩 MV) ‘ (ΊΛ MV) ‘ (M MV) ‘ (ΓΛ MV) ‘ (ΙΛ MV) [9Z.20]
‘(ΗΛ
MV) ‘ (0Λ MV) ‘ (ΗΛ MV) ‘ (3Λ MV) ‘ (0Λ MV) ‘ (3Λ MV) ‘ (9Λ MV) ‘ (VA MV) ‘ Ol ‘ [9Z.20]
OV) ‘ (91 iOV) ‘ (VI iOV) ‘ (ΖΛ iOV) ‘ (ΑΛ iOV) ‘ (ΧΛ iOV) ‘ (M iOV) ‘ (ΛΛ ‘ [VLZO]
OV) ‘ (ΠΛ iOV) ‘ CLA iOV) ‘ (SA iOV) ‘ (M iOV) ‘ (GA iOV) ‘ (dA iOV) ‘ (0Λ ‘ [0Z.2O]
OV) ‘ (NA iOV) ‘ (嫩 iOV) ‘(ΊΛ iOV) ‘ (M iOV) ‘ (ΓΛ iOV) ‘ (ΙΛ iOV) ‘ (ΗΛ ‘ [ZLZO]
OV) ‘ (0Λ iOV) ‘ (ΗΛ iOV) ‘ (3Λ iOV) ‘ (0Λ iOV) ‘ (3Λ iOV) ‘ (9Λ iOV) ‘ (VA ‘ [ΙΖ.20]
r\\ τ\ 6 /r\ Ii i k τλ τ\ 6 /η ιι 6 κίλ τ\ 6 /λ τιι ί k τλ τ\ 6 /ri » ί ι τλ τ\ ί / τ » ί k τλ τ\ 6 /\r » ί k τλ τ\ ί / ιι » ί k τλ τ\ Γλ , ~»λΊ
CN 10 228172 B 说明 书 36/135 页[0383 (BS,VX) (BS,VY) (BS,VZ) (BS,WA) (BS,WB) (BS,WC) (BT,VA) (BT,VB),[0384 (BT,VC) (BT,VD) (BT,VE) (BT,VF) (BT,VG) (BT,VH) (BT, VI) (BT,VJ),[0385 (BT,VK) (BT,VL) (BT,VM) (BT,VN) (BT,VO) (BT,VP) (BT,VQ) (BT,VR),[0386 (BT,VS) (BT,VT) (BT,VU) (BT,VV) (BT,Vff) (BT,VX) (BT,VY) (BT,VZ),[0387 (BT,WA) (BT,WB) (BT,WC) (BU,VA) (BU,VB) (BU,VC) (BU,VD) (BU,VE),[0388 (BU,VF) (BU,VG) (BU,VH) (BU, VI) (BU,VJ) (BU,VK) (BU,VL) (BU,VM),[0389 (BU,VN) (BU,VO) (BU,VP) (BU,VQ) (BU,VR) (BU,VS) (BU,VT) (BU,VU),[0390 (BU,VV) (BU,Vff) (BU,VX) (BU,VY) (BU,VZ) (BU,WA) (BU,WB) (BU,WC),[0391 (BV, VA) (BV, VB) (BV, VC) (BV, VD) (BV, VE) (BV, VF) (BV, VG) (BV, VH),[0392 (BV, VI) (BV,VJ) (BV, VK) (BV, VL) (BV, VM) (BV, VN) (BV, VO) (BV, VP),[0393 (BV,VQ) (BV, VR) (BV, VS) (BV, VT) (BV, VU) (BV, VV) (BV, Vff) (BV, VX),[0394 (BV, VY) (BV, VZ) (BV, WA) (BV, WB) (BV, WC) (BW, VA) (BW, VB) (BW, VC), [0395 (BW, VD) (BW, VE) (BW, VF) (BW, VG) (BW, VH) (BW, VI) (BW, VJ) (BW, VK),[0396 (BW, VL) (BW, VM) (BW, VN) (BW, VO) (BW, VP) (BW, VQ) (BW, VR) (BW, VS),[0397 (BW, VT) (BW, VU) (BW, VV) (BW, Vff) (BW, VX) (BW, VY) (BW, VZ) (BW, WA),[0398 (BW, WB) (BW, WC) (BX,VA) (BX,VB) (BX,VC) (BX,VD) (BX,VE) (BX,VF),[0399 (BX,VG) (BX,VH) (BX, VI) (BX,VJ) (BX,VK) (BX,VL) (BX,VM) (BX,VN),[0400 (BX,VO) (BX,VP) (BX,VQ) (BX,VR) (BX,VS) (BX,VT) (BX,VU) (BX,VV),[0401 (BX,Vff) (BX,VX) (BX,VY) (BX,VZ) (BX,WA) (BX,WB) (BX,WC) (BY, VA),[0402 (BY, VB) (BY, VC) (BY, VD) (BY, VE) (BY, VF) (BY, VG) (BY, VH) (BY, VI),[0403 (BY, VJ) (BY, VK) (BY, VL) (BY, VM) (BY, VN) (BY, VO) (BY, VP) (BY, VQ),[0404 (BY, VR) (BY, VS) (BY, VT) (BY, VU) (BY, VV) (BY, Vff) (BY, VX) (BY, VY),[0405 (BY, VZ) (BY, WA) (BY, WB) (BY, WC) (BZ,VA) (BZ,VB) (BZ,VC) (BZ,VD),[0406 (BZ,VE) (BZ,VF) (BZ,VG) (BZ,VH) (BZ, VI) (BZ,VJ) (BZ,VK) (BZ,VL),[0407 (BZ,VM) (BZ,VN) (BZ,VO) (BZ,VP) (BZ,VQ) (BZ,VR) (BZ,VS) (BZ,VT),[0408 [0409 (BZ,VU) (BZ,WC) (BZ,VV) (BZ,Vff) (BZ,VX) (BZ,VY) (BZ,VZ) (BZ,WA) (BZ,WB),[0410 (CA, VA) (CA, VB) (CA, VC) (CA, VD) (CA, VE) (CA, VF) (CA, VG) (CA, VH),[0411 (CA, VI) (CA,VJ) (CA, VK) (CA, VL) (CA, VM) (CA, VN) (CA, VO) (CA, VP),[0412 (CA,VQ) (CA, VR) (CA, VS) (CA, VT) (CA, VU) (CA, VV) (CA, Vff) (CA, VX),[0413 (CA, VY) (CA, VZ) (CA, WA) (CA, WB) (CA, WC) (CB,VA) (CB,VB) (CB,VC),[0414 (CB,VD) (CB,VE) (CB,VF) (CB,VG) (CB,VH) (CB, VI) (CB,VJ) (CB,VK),[0415 (CB,VD) (CB,VM) (CB,VN) (CB,VO) (CB,VP) (CB,VQ) (CB,VR) (CB,VS),[0416 (CB,VT) (CB,VU) (CB,VV) (CB,Vff) (CB,VX) (CB,VY) (CB,VZ) (CB,WA),[0417 (CB,WB) (CB,WC) (CC,VA) (CC,VB) (CC,VC) (CC,VD) (CC,VE) (CC,VF),[0418 (CC,VG) (CC,VH) (CC, VI) (CC,VJ) (CC,VK) (CC,VL) (CC,VM) (CC,VN),[0419 (CC,VO) (CC,VP) (CC,VQ) (CC,VR) (CC, VS) (CC,VT) (CC,VU) (CC,VV),[0420 (CC,Vff) (CC,VX) (CC,VY) (CC,VZ) (CC,WA) (CC,WB) (CC,WC) (CD,VA),[0421 (CD, YB) (CD,VC) (CD,VD) (CD, VE) (CD,VF) (CD,VG) (CD,VH) (CD,VI),
CN 101228172 BH·1COCTI〔0537 〔0538 〔0539 〔0540 〔0541 〔0542 〔0543 〔0544 〔0545 〔0546 〔0547 〔0548 〔0549 〔0550 〔0551 〔0552 〔0553 〔0554 〔0555 〔0556 〔0557 〔0558 〔0559 〔0560 〔0561 〔0562 〔0563 〔0564 〔0565 〔0566 〔0S7 〔0568 〔0569 〔0570 〔0571 〔0572 〔0573 〔05741--10575Gr Vw) (DJ, VB) GJ, S (DJ, VR) GJ, Vz)P Vs(DK, VsP VsP S(Dr S(Dr Vp) (Dr Vx) (DM, VC) (DM, S (DM, VQ) (DM, Vx) (DN, Vs (DN, S (DN, VR) (DN, SGr Vx), GJ, VC), (DJ, VK),GJ, vs), GJ, S , (DK, VF), (DK, VN), (DK, Vv),(Dr M),(Dr VI), (Dr VQ), (Dr VY), (DM, VD), (DM, VK), (DM, VR), (DM, VY), (DN, VC), (DN, VK), (DN, vs),GrsGJ, VD) GJ, S GJ, VT) (DJ, WB) (DK, Vs (DK, Vo) (DK, Vw) (Dr Vs(Dr S(Dr VR)(Dr S(DM, VE) (DM, S (DM, vs) (DM, S (DN, VD) (DN, S (DN, VT)Gr Vz), (DJ, VE), GJ, VM), (DJ, Vs , (DJ, Wc), (DK, S , (DK, VP), (DK, Vx),(Dr VC), (Dr VK), (Dr vs),(Dr M),(DM, VF), (DM, Vs , (DM, VT), (DM, M), (DN, Vs , (DN, Vs ,,(DN, Vs ,Gr M) (DJ, VF) GJ, Vs GJ, w) (DK, M) (DK, VI) (DK, VQ) (DK, VY) (Dr VD)(Dr S(Dr VT) (Dr Ws (DM, VG) (DM, VN) (DM, Vu) (DM, WB) (DN, VF) (DN, VN) (DN, Vv)Gr Ws (DJ, VG) GJ, Vs GJ, Vw) (DK, Vs (DK, S (DK, VR) (DK, S(Dr Vs (Dr Vs(Dr Vs(Dr S(DM, S (DM, Vs (DM, Vv) (DM, Wc) (DN, Vs (DN, Vo),(DN, w)Gr SGJ, Vs (DJ, VP) GJ, S (DK, VC) (DK, VK) (DK, vs) (DK, M) (Dr VF) (Dr VN) (Dr Vv) (DM, M) (DM, VI) (DM, VP) (DM, Vw) (DN, M) (DN, S (DN, VP),(DN, Vx)GJ, M), GJ, VI), (DJ, VQ), GJ, VY), (DK, VD), (DK, S , (DK, VT), (DK, Ws , (Dr VG), (Dr Vs , (Dr Vw), (DM, VB),(DN, VI), (DN, VQ), -(DN, VY)-(Do(DN, WA),(DN, WB),(DN, Wc),(Do, VA),(Do, VB),(Do, VC),VD),(Do, VE),(Do, VF),(Do, VG),(Do, VH),(Do, VI),(Do, VJ),(Do, VK),(D 0, VL),(Do, Vs , (Do, VN),(Do, Vs , (Do, VP),(Do, VQ),(Do, VR),(Do ,vs),(Do, VT),(Do, Vs , (Do, Vv),(Do, Vw),(Do, Vx),(Do, VY),(Do, Vz), (Do, WA),(Do, WB),(Do, Wc),(Dp, VA),(Dp, VB),(Dp, VC),(Dp, VD),(Dp, VE) (Dp, VF),(Dp, VG),(Dp, VH),(Dp, VI),(Dp, VJ),(Dp, VK),(Dp, VL),(Dp, VM)(Dp, VF), (Dp, VG),(Dp, VN),(Dp, Vs , (Dp, VP),(Dp, VQ),(Dp, VR), (Dp, Vv),(Dp, Vw),(Dp, Vx),(Dp, VY),(Dp, Vz), (DQ, VA),(DQ, VB),(DQ, VC),(DQ, VD),(DQ, VE), (DQ, VI),(DQ, VJ),(DQ, VK),(DQ, VL),(DQ, Vs , (DQ, VQ),(DQ, VR),(DQ, vs),(DQ, VT),(DQ, Vs , (DQ, VY),(DQ, Vz),(DQ, WA),(DQ, WB),(DQ, Wc), (DR, VD), (DR, VE), (DR, VF), (DR, VG), (DR, VH), (DR, VL),(DR, VM),(DR, VN),(DR, Vo),(DR, VP), (DR, VT),(DR, Vu),(DR, Vv),(DR, Vw),(DR, Vx), (DR, WB), (DR, Wc), (Ds, VA), (Ds, VB), (Ds, VC), (Ds, VG),(Ds, VH),(Ds, VI),(Ds, VJ),(Ds, VK), (Ds, Vo),(Ds, VP),(Ds, VQ),(Ds, VR),(Ds, vs), (Ds, Vw),(Ds, Vx),(Ds, VY),(Ds, Vz),(Ds, WA), (DT, VB), (DT, VC),(DT, VD), (DT, VE),(DT, VF),(Dp, vs),(Dp, VT),(Dp, Vs 一 (Dp, WA),(Dp, WB),(Dp, Wc), (DQ, VF),(DQ, VG),(DQ, VH), (DQ, VN),(DQ, Vs , (DQ, VP), (DQ, Vv),(DQ, Vw),(DQ, Vx), (DR, VA),(DR, VB),(DR, VC), (DR, VI),(DR, VJ),(DR, VK), (DR, VQ),(DR, VR),(DR, vs), (DR, VY),(DR, Vz),(DR, WA), (Ds, VD), (Ds, VE), (Ds, VF), (Ds, VL),(Ds, Vs , (Ds, VN), (Ds, VT),(Ds, Vs , (Ds, Vv), (Ds, WB), (Ds, Wc), (DT, VA), (DT, VG),(DT, VH),(DT, VI),[0576] (DT, VJ),(DT, VK),(DT, VL),(DT, VM),(DT, VN),(DT, VO),(DT, VP),(DT, VQ),
[0577] (DT, VR),(DT, VS),(DT, VT),(DT, VU),(DT, VV),(DT, Vff),(DT, VX),(DT, VY),
[0578] (DT, VZ),(DT, WA),(DT, WB),(DT, WC),(DU, VA),(DU, VB),(DU, VC),(DU, VD),
[0579] (DU, VE),(DU, VF),(DU, VG),(DU, VH),(DU, VI),(DU, VJ),(DU, VK),(DU, VL),
[0580] (DU, VM),(DU, VN),(DU, VO),(DU, VP),(DU, VQ),(DU, VR),(DU, VS),(DU, VT),
[0581] (DU, VU),(DU, VV),(DU, Vff),(DU, VX),(DU, VY),(DU, VZ),(DU, WA),
[0582] (DU, WB),(DU, WC),(DV, VA),(DV, VB),(DV, VC),(DV, VD),(DV, VE),(DV, VF),
[0583] (DV, VG),(DV, VH),(DV, VI),(DV, VJ),(DV, VK),(DV, VL),(DV, VM),(DV, VN),
[0584] (DV, VO),(DV, VP),(DV, VQ),(DV, VR),(DV, VS),(DV, VT),(DV, VU),(DV, VV),
[0585] (DV, Vff),(DV, VX),(DV, VY),(DV, VZ),(DV, WA),(DV, WB),(DV, WC),(Dff, VA),
[0586] (Dff, VB),(Dff, VC),(Dff, VD),(Dff, VE),(Dff, VF),(Dff, VG),(Dff, VH),(Dff, VI),
[0587] (Dff, VJ),(Dff, VK),(Dff, VL),(Dff, VM),(Dff, VN),(Dff, VO),(Dff, VP),
[0588] (Dff, VQ),(Dff, VR),(Dff, VS),(Dff, VT),(Dff, VU),(Dff, VV),(Dff, Vff),
[0589] (Dff, VX),(Dff, VY),(Dff, VZ),(Dff, WA),(Dff, WB),(Dff, WC),(DX, VA),(DX, VB),
[0590] (DX, VC),(DX, VD),(DX, VE),(DX, VF),(DX, VG),(DX, VH),(DX, VI),(DX, VJ),
[0591] (DX, VK),(DX, VL),(DX, VM),(DX, VN),(DX, VO),(DX, VP),(DX, VQ),(DX, VR),
[0592] (DX, VS),(DX, VT),(DX, VU),(DX, VV),(DX, Vff),(DX, VX),(DX, VY),(DX, VZ),
[0593] (DX, WA),(DX, WB),(DX, WC),(DY, VA),(DY, VB),(DY, VC),(DY, VD),(DY, VE),
[0594] (DY, VF),(DY, VG),(DY, VH),(DY, VI),(DY, VJ),(DY, VK),(DY, VL),(DY, VM),
[0595] (DY, VN),(DY, VO),(DY, VP),(DY, VQ),(DY, VR),(DY, VS),(DY, VT),(DY, VU),
[0596] (DY, VV),(DY, Vff),(DY, VX),(DY, VY),(DY, VZ),(DY, WA),(DY, WB),(DY, WC),
[0597] (DZ, VA),(DZ, VB),(DZ, VC),(DZ, VD),(DZ, VE),(DZ, VF),(DZ, VG),(DZ, VH),
[0598] (DZ, VI),(DZ, VJ),(DZ, VK),(DZ, VL),(DZ, VM),(DZ, VN),(DZ, VO),(DZ, VP),
[0599] (DZ, VQ),(DZ, VR),(DZ, VS),(DZ, VT),(DZ, VU),(DZ, VV),(DZ, Vff),(DZ, VX),
[0600] (DZ, VY),(DZ, VZ),(DZ, WA),(DZ, WB),(DZ, WC),
[0601] (EA, VA),(EA, VB),(EA, VC),(EA, VD),(EA, VE),(EA, VF),(EA, VG),(EA, VH),
[0602] (EA, VI),(EA, VJ),(EA, VK),(EA, VL),(EA, VM),(EA, VN),(EA, VO),(EA, VP),
[0603] (EA, VQ),(EA, VR),(EA, VS),(EA, VT),(EA, VU),(EA, VV),(EA, Vff),(EA, VX),
[0604] (EA, VY),(EA, VZ),(EA, WA),(EA, WB),(EA, WC),(EB, VA),(EB, VB),(EB, VC),
[0605] (EB, VD),(EB, VE),(EB, VF),(EB, VG),(EB, VH),(EB, VI),(EB, VJ),(EB, VK),
[0606] (EB, VL),(EB, VM),(EB, VN),(EB, VO),(EB, VP),(EB, VQ),(EB, VR),(EB, VS),
[0607] (EB, VT),(EB, VU),(EB, VV),(EB, Vff),(EB, VX),(EB, VY),(EB, VZ),(EB, WA),
[0608] (EB, WB),(EB, WC),(EC, VA),(EC, VA),(EC, VB),(EC, VB),(EC, VC),(EC, VD),
[0609] (EC, VE),(EC, VF),(EC, VG),(EC, VH),(EC, VI),(EC, VJ),(EC, VK),(EC, VL),
[0610] (EC, VM),(EC, VN),(EC, VO),(EC, VP),(EC, VQ),(EC, VR),(EC, VS),(EC, VT),
[0611] (EC, VU),(EC, VV),(EC, Vff),(EC, VX),(EC, VY),(EC, VZ),(EC, WA),(EC, WB),
[0612] (EC, WC),(ED, VC),(ED, VD),(ED, VE),(ED, VF),(ED, VG),(ED, VH),(ED, VI),
[0613] (ED, VJ),(ED, VK),(ED, VL),(ED, VM),(ED, VN),(ED, VO),(ED, VP),(ED, VQ),
[0614] (ED, VR),(ED, VS),(ED, VT),(ED, VU),(ED, VV),(ED, Vff),(ED, VX),(ED, VY),[0615] (ED, VZ) (ED, WA), (ED, WB), (ED, WC), (EE, VA), (EE, VB), (EE, VC), (EE, VD),[0616] (EE, VE) (EE, VF), (EE, VG), (EE, VH), (EE, VI), (EE, VJ), (EE, VK), (EE, VL),[0617] (EE, VM) (EE, VN), (EE, VO), (EE, VP), (EE, VQ), (EE, VR), (EE, VS), (EE, VT),[0618] (EE, VU) (EE, VV), (EE, Vff), (EE, VX), (EE, VY), (EE, VZ), (EE, WA), (EE, WB),[0619] (EE, WC) (EF,VA), (EF,VB), (EF,VC), (EF,VD), (EF,VE), (EF,VF), (EF,VG),[0620] (EF,VH) (EF, VI), (EF,VJ), (EF,VK), (EF,VL), (EF,VM), (EF,VN), (EF,VO),[0621] (EF,VP) (EF,VQ), (EF,VR), (EF,VS), (EF,VT), (EF,VU), (EF,VV), (EF,Vff),[0622] (EF,VX) (EF,VY), (EF,VZ), (EF,WA), (EF,WB), (EF,WC), (EG, VA), (EG, VB), [0623] (EG, VC) (EG, VD), (EG, VE), (EG, VF), (EG, VG), (EG, VH), (EG, VI), (EG, VJ),[0624] (EG, VK) (EG, VL), (EG, VM), (EG, VN), (EG, VO), (EG, VP), (EG, VQ), (EG, VR),[0625] (EG, VS) (EG, VT), (EG, VU), (EG, VV), (EG, Vff), (EG, VX), (EG, VY), (EG, VZ),[0626] (EG, WA) (EG, WB), (EG, WC), (EH, VA), (EH, VB), (EH, VC), (EH, VD), (EH, VE),[0627] (EH, VF) (EH, VG), (EH, VH), (EH, VI), (EH, VJ), (EH, VK), (EH, VL), (EH, VM),[0628] (EH, VN) (EH, VO), (EH, VP), (EH, VQ), (EH, VR), (EH, VS), (EH, VT), (EH, VU),[0629] (EH, VV) (EH, Vff), (EH, VX), (EH, VY), (EH, VZ), (EH, WA), (EH, WB), (EH, WC),[0630] (EI,VA) (EI,VB), (EI,VC) (EI,VD) ,(EI,VE) ,(EI,VF) ,(EI,VG) ,(EI,VH),(El, VI) 9 [0631] (EI,VJ) (EI,VK), (EI,VL) (EI,VM) ,(EI,VN) ,(EI,VO) ,(EI,VP) ,(EI,VQ),(EI,VR) 9 [0632] (EI,VS) (EI,VT), (El, VU), (EI,VV), (EI,Vff), (El, VX), (El, VY), (El, VZ),[0633] (EI,WA) (EI,WB), (EI,WC), (EJ,VA), (EJ,VB), (EJ,VC), (EJ,VD), (EJ,VE),[0634] (EJ,VF) (EJ,VG), (EJ,VH), (EJ, VI), (EJ,VJ), (EJ,VK), (EJ,VL), (EJ,VM),[0635] (EJ,VN) (EJ,VO), (EJ,VP), (EJ,VQ), (EJ,VR), (EJ, VS), (EJ,VT), (EJ,VU),[0636] (EJ,VV) (EJ,Vff), (EJ,VX), (EJ,VY), (EJ,VZ), (EJ,WA), (EJ,WB), (EJ,WC),[0637] (EK,VA) (EK,VB), (EK,VC), (EK,VD), (EK,VE), (EK,VF), (EK,VG), (EK,VH),[0638] (ΕΚ, VI) (EK,VJ), (EK,VK), (EK,VL), (EK,VM), (EK,VN), (EK,VO), (EK,VP),[0639] (EK,VQ) (EK,VR), (EK,VS), (EK,VT), (EK,VU), (EK,VV), (EK,Vff), (EK,VX),[0640] (EK,VY) (EK,VZ), (EK,WA), (EK,WB), (EK,WC), (EL, VA), (EL, VB), (EL, VC),[0641] (EL, VD) (EL, VE), (EL, VF), (EL, VG), (EL, VH), (EL, VI), (EL, VJ), (EL, VK),[0642] (EL, VL) (EL, VM), (EL, VN), (EL, VO), (EL, VP), (EL, VQ), (EL, VR), (EL, VS),[0643] (EL, VT) (EL, VU), (EL, VV), (EL, Vff), (EL, VX), (EL, VY), (EL, VZ), (EL, WA),[0644] (EL, WB) (EL, WC), (EM, VA), (EM, VB), (EM, VC), (EM, VD), (EM, VE), (EM, VF),[0645] (EM, VG) (EM, VH), (EM, VI), (EM, VJ), (EM, VK), (EM, VL), (EM, VM), [0646] (EM, VN) (EM, VO), (EM, VP), (EM, VQ), (EM, VR), (EM, VS), (EM, VT), [0647] (EM, VU) (EM, VV), (EM, Vff), (EM, VX), (EM, VY), (EM, VZ), (EM, WA), [0648] (EM, WB) (EM, WC), (EN, VA), (EN, VB), (EN, VC), (EN, VD), (EN, VE), (EN, VF),[0649] (EN, VG) (EN, VH), (ΕΝ, VI), (EN, VJ), (EN, VK), (EN, VL), (EN, VM), (EN, VN),[0650] (EN, VO) (EN, VP), (EN, VQ), (EN, VR), (EN, VS), (EN, VT), (EN, VU), (EN, VV),[0651] (EN, Vff) (EN, VX), (EN, VY), (EN, VZ), (EN, WA), (EN, WB), (EN, WC), (EO,VA),
[0691] (EY, Vff) (EY, VX) (EY, VY) (EY, VZ), (EY, WA), (EY, WB), (EY, WC), (EZ,VA),[0692] (EZ,VB) (EZ,VC) (EZ,VD) (EZ,VE), (EZ,VF), (EZ,VG), (EZ,VH), (EZ, VI),[0693] (EZ,VJ) (EZ,VK) (EZ,VL) (EZ,VM), (EZ,VN), (EZ,VO), (EZ,VP), (EZ,VQ),[0694] (EZ,VR) (EZ,VS) (EZ,VT) (EZ,VU), (EZ,VV), (EZ,Vff), (EZ,VX), (EZ,VY),[0695] (EZ,VZ) (EZ,WA) (EZ,WB) (EZ,WC), [0696] (FA, VA) (FA, VB) (FA, VC) (FA, VD), (FA, VE), (FA, VF), (FA, VG), (FA, VH),[0697] (FA, VI) (FA, VJ) (FA, VK) (FA, VL), (FA, VM), (FA, VN), (FA, VO), (FA, VP),[0698] (FA, VQ) (FA, VR) (FA, VS) (FA, VT), (FA, VU), (FA, VV), (FA, Vff), (FA, VX), [0699] (FA, VY) (FA, VZ) (FA, WA) (FA, WB), (FA, WC), (FB,VA), (FB, VB), (FB,VC),[0700] (FB, VD) (FB, VE) (FB, VF) (FB, VG), (FB,VH), (FB, VI), (FB,VJ), (FB, VK),[0701] (FB,VL) (FB,VM) (FB,VN) (FB,VO), (FB, VP), (FB,VQ), (FB,VR), (FB,VS),[0702] (FB,VT) (FB, VU) (FB,VV) (FB,Vff), (FB,VX), (FB,VY), (FB,VZ), (FB, WA),[0703] (FB, WB) (FB, WC) (FC,VA) (FC,VA), (FC,VB), (FC,VB), (FC,VC), (FC,VD),[0704] (FC,VE) (FC,VF) (FC,VG) (FC,VH), (FC, VI), (FC,VJ), (FC,VK), (FC,VL),[0705] (FC,VM) (FC,VN) (FC,VO) (FC,VP), (FC,VQ), (FC,VR), (FC,VS), (FC,VT),[0706] (FC,VU) (FC,VV) (FC,Vff) (FC,VX), (FC,VY), (FC,VZ), (FC,WA), (FC,WB),[0707] (FC,WC) (FD,VC) (FD, VD) (FD, VE), (FD, VF), (FD, VG), (FD,VH), (FD, VI),[0708] (FD,VJ) (FD, VK) (FD,VL) (FD,VM), (FD,VN), (FD,VO), (FD, VP), (FD,VQ),[0709] (FD,VR) (FD,VS) (FD,VT) (FD, VU), (FD,VV), (FD,Vff), (FD,VX), (FD,VY),[0710] (FD,VZ) (FD,WA) (FD, WB) (FD, WC), (FE, VA), (FE, VB), (FE, VC), (FE, VD),[0711] (FE, VE) (FE, VF) (FE, VG) (FE, VH), (FE,VI), (FE,VJ), (FE, VK), (FE,VL),[0712] (FE, VM) (FE, VN) (FE, VO) (FE, VP), (FE,VQ), (FE, VR), (FE, VS), (FE, VT),[0713] (FE, VU) (FE, VV) (FE, Vff) (FE, VX), (FE, VY), (FE, VZ), (FE, WA), (FE, WB),[0714] (FE, WC) (FF,VA) (FF, VB) (FF,VC), (FF, VD), (FF, VE), (FF, VF), (FF, VG),[0715] (FF,VH) (FF, VI) (FF,VJ) (FF, VK), (FF,VL), (FF,VM), (FF,VN), (FF,VO),[0716] (FF, VP) (FF,VQ) (FF,VR) (FF,VS), (FF,VT), (FF, VU), (FF,VV), (FF,Vff),[0717] (FF,VX) (FF,VY) (FF,VZ) (FF,WA), (FF, WB), (FF, WC), (FG,VA), (FG, VB),[0718] (FG,VC) (FG, VD) (FG, VE) (FG, VF), (FG, VG), (FG,VH), (FG, VI), (FG,VJ),[0719] (FG, VK) (FG,VL) (FG,VM) (FG,VN), (FG,VO), (FG, VP), (FG,VQ), (FG,VR),[0720] (FG,VS) (FG,VT) (FG, VU) (FG,VV), (FG,Vff), (FG,VX), (FG,VY), (FG,VZ),[0721] (FG, WA) (FG, WB) (FG, WC) (FH, VA), (FH, VB), (FH, VC), (FH, VD), (FH, VE),[0722] (FH, VF) (FH, VG) (FH, VH) (FH, VI), (FH, VJ), (FH, VK), (FH, VL), (FH, VM),[0723] (FH, VN) (FH, VO) (FH, VP) (FH, VQ), (FH, VR), (FH, VS), (FH, VT), (FH, VU),[0724] (FH, VV) (FH, Vff) (FH, VX) (FH, VY), (FH, VZ), (PH, WA), (FH, WB), (FH, WC),[0725] (FI, VA) (FI, VB) (FI, VC) ,(FI, VD) ,(FI, VE) ,(FI, VF), (FI, VG), (FI, VH), (FI,VI) 9 [0726] (FI, VJ) (FI, VK) (FI, VL),(FI, VM),(FI, VN),(FI, VO),(FI, VP),(FI, VQ), (FI, VR), [0727] (FI, VS) (FI, VT) (FI, VU),(FI, VV),(FI, Vff),(FI, VX),(FI, VY),(FI, VZ),
00) ‘ (M iOO) ‘ (GA iOO) ‘ (dA iOO) ‘ (0Λ iOO) ‘ (NA iOO) ‘ (嫩 iOO) ‘(ΊΛ ‘0 [ε·]
O) ‘ (Μ iOO) ‘ (ΓΛ iOO) ‘ (ΙΛ iOO) ‘ (ΗΛ iOO) ‘ (0Λ iOO) ‘ (dA iOO) ‘ (3Λ iOO) ‘ (0Λ ‘ [2酬
00) ‘ (3Λ iOO) ‘ (9Λ iOO) ‘ (VA iOO) ‘(31 iNO) ‘ (91 iNO) ‘ (VI iNO) ‘ (ΖΛ iNO)[卟80]
‘ (ΑΛ iNO) ‘ (ΧΛ iNO) ‘ (M iNO) ‘ (ΛΛ iNO) ‘ (ΠΛ iNO) ‘ (ΧΛ iNO) ‘ (SA iNO) ‘ (M iNO) [O·]
‘ (GA iNO) ‘ (dA iNO) ‘ (0Λ iNO) ‘ (NA iNO) ‘ (嫩 iNO) ‘(ΊΛ iNO) ‘ (M iNO) ‘ (ΓΛ iNO) [6080]
‘(ΙΛ ‘NO) ‘ (ΗΛ iNO) ‘ (ΟΛ iNO) ‘ (ΗΛ iNO) ‘ (3Λ iNO) ‘((ΊΛ iNO) ‘(ΟΛ ‘NO) ‘ (9Λ iNO) [8080]
‘ (VA iNO) ‘ Ol iWO) ‘ (91 iWO) ‘ (VI iWO) ‘(ΖΛ ‘【))‘ (ΑΛ iWO) ‘ (ΧΛ iWO) [Z.08O]
‘ (M iWO) ‘ (ΛΛ iWO) ‘ (ΠΛ iWO) ‘ (ΧΛ iWO) ‘ (SA iWO) ‘ (M iWO) ‘ (GA iWO) [9080]
‘ (dA iWO) ‘ (0Λ iWO) ‘ (NA iWO) ‘ (嫩 iWO) ‘(ΊΛ iWO) ‘ (M iWO) ‘ (ΓΛ iWO) [9080]
‘(ΙΛ ‘W3) ‘ (ΗΛ iWO) ‘ (ΟΛ iWO) ‘ (ΗΛ iWO) ‘ (3Λ iWO) ‘((ΊΛ iWO) ‘(3Λ ‘W3)[扒80]
‘ (9Λ iWO) ‘ (VA iWO) ‘ Ol iIO) ‘ (91 iIO) ‘ (VI iIO) ‘ (ΖΛ iIO) ‘ (ΑΛ iIO) ‘ (ΧΛ iIO) [0080]
‘ (M iIO) ‘ (ΛΛ iIO) ‘ (ΠΛ iIO) ‘ (ΧΛ iIO) ‘ (SA iIO) ‘ (M iIO) ‘ (GA iIO) ‘ (dA iIO) [2080]
‘ (0Λ iIO) ‘ (NA iIO) ‘ (嫩 iIO) ‘ (ΊΛ iIO) ‘ (M iIO) ‘ (ΓΛ iIO) ‘ (ΙΛ iIO) ‘ (ΗΛ iIO) [1080]
‘ (0Λ iIO) ‘ (ΗΛ iIO) ‘ (3Λ iIO) ‘ (0Λ iIO) ‘ (3Λ iIO) ‘ (9Λ iIO) ‘ (VA iIO) ‘(31 ‘抑[0080]‘ (91 ‘邪)‘ (VI ‘邪)‘ (ΖΛ ‘邪)‘ (ΑΛ ‘邪)‘ (ΧΛ ‘邪)‘ (M ‘邪)‘ (ΛΛ ‘邪)‘ (ΠΛ ‘邪)[6280]
‘ (JA ‘抑 ‘ (SA ‘抑 ‘ (M ‘抑 ‘ (GA ‘抑 ‘ (dA ‘抑 ‘ (0Λ ‘抑 ‘ (NA ‘抑‘(嫩‘抑[8280]
‘(ΊΛ ‘抑 ‘ (Μ ‘抑 ‘(ΓΛ ‘抑 ‘(ΙΛ ‘抑 ‘ (ΗΛ ‘抑 ‘ (ΟΛ ‘抑 ‘ (ΗΛ ‘抑 ‘ (3Λ ‘抑[Ζ.280]
‘((ΊΛ ‘)©) ‘ (DA ‘)©) ‘ (9Λ ‘)©) ‘ (VA ‘)©) ‘ (DM 4Γθ) ‘ (914Γθ) ‘ (VM 4Γθ) ‘ (ΖΛ 4Γθ) [9280]
‘ (AA iFO) ‘ (ΧΛ 4Γ0) ‘ (MA iFO) ‘ (ΛΛ 4Γθ) ‘ (ΠΛ 4Γθ) ‘ (ΧΛ 4Γθ) ‘ (SA iFO) ‘ (Μ iFO) [9280]
‘ (GA 4Γ0) ‘ (dA iFO) ‘ (ΟΛ 4Γ0) ‘ (ΝΛ 4Γθ) ‘ (ΜΛ 4Γθ) ‘ (ΊΛ 4Γθ) ‘ (Μ iFO) ‘ (ΓΛ 4Γθ)[於80]
‘ (ΙΛ 4Γ0) ‘ (ΗΛ 4Γ0) ‘ (ΟΛ 4Γθ) ‘ (AA iFO) ‘ (3Α iFO) ‘((ΊΛ 4Γθ) ‘ (OA iFO) ‘ (QA iFO) [0280]
‘ (VA 4Γ0) ‘ (DM iIO) ‘ (91 iIO) ‘ (VM iIO) ‘ (ΖΛ iIO) ‘ (AA iIO) ‘ (ΧΛ iIO) ‘ (MA iIO) [2280]
‘ (ΛΛ iIO) ‘ (ΠΛ iIO) ‘ CLA iIO) ‘ (SA iIO) ‘ (M iIO) ‘ (GA iIO) ‘ (dA iIO) ‘ (0Λ iIO) [1280]
‘ (NA iIO) ‘ (嫩 iIO) ‘(ΊΛ iIO) ‘ (M iIO) ‘ (ΓΛ iIO) ‘ (ΙΛ iIO) ‘ (ΗΛ iIO) ‘ (0Λ iIO) [0280]
‘ (ΗΛ iIO) ‘ (3Λ iIO) ‘ (0Λ iIO) ‘ (DA iIO) ‘ (9Λ iIO) ‘ (VA iIO) ‘ (DM iHO) ‘ (91 iHO) [6180]
‘ (VM iHO) ‘(ΖΛ ‘Hf)) ‘ (AA iHO) ‘ (ΧΛ iHO) ‘ (MA iHO) ‘ (ΛΛ iHO) ‘ (ΠΛ iHO) [8180]
‘ (ΧΛ iHO) ‘ (SA iHO) ‘ (M iHO) ‘ (GA iHO) ‘ (dA iHO) ‘ (0Λ iHO) ‘ (NA iHO) ‘ (嫩 iHO) [L180]
‘(ΊΛ ‘Hf)) ‘ (M iHO) ‘(ΓΛ ‘Hf)) ‘(ΙΛ ‘Hf)) ‘ (ΗΛ iHO) ‘ (ΟΛ iHO) ‘ (ΗΛ iHO) ‘ (3Λ iHO) [9180]
‘((ΊΛ iHO) ‘(ΟΛ ‘Hf)) ‘ (9Λ iHO) ‘ (VA iHO) ‘(31 iOO) ‘ (91 iOO) ‘ (VI iOO) [9180]
‘(ΖΛ ‘邮 ‘ (ΑΛ iOO) ‘ (ΧΛ iOO) ‘ (M iOO) ‘ (ΛΛ iOO) ‘ (ΠΛ iOO) ‘ (JA ‘邮 ‘(SA ‘邮[W80]
‘ (M iOO) ‘ (GA iOO) ‘ (dA iOO) ‘ (ΟΛ iOO) ‘ (NA iOO) ‘ (ΜΛ iOO) ‘(ΊΛ iOO) ‘ (M iOO) [0180]
‘(ΓΛ ‘邮 ‘(ΙΛ ‘邮 ‘ (ΗΛ iOO) ‘ (ΟΛ iOO) ‘ (ΗΛ iOO) ‘ (3Λ iOO) ‘ (0Λ iOO) ‘(3Λ ‘邮[2180]
‘ (9Λ iOO) ‘ (VA iOO) ‘ (DM iHO) ‘ (91 iHO) ‘ (VM iHO) ‘(ΖΛ ‘姻 ‘ (AA iHO) ‘ (ΧΛ iHO) [U80]
‘ (MA iHO) ‘ (ΛΛ iHO) ‘ (ΠΛ iHO) ‘ (ΧΛ iHO) ‘ (SA iHO) ‘ (M iHO) ‘ (GA iHO) ‘ (dA iHO) [0180]
‘ (ΟΛ ‘姻 ‘ (NA iHO) ‘ (ΜΛ iHO) ‘ (ΊΛ ‘姻 ‘ (Μ iHO) ‘ (ΓΛ ‘姻 ‘(ΙΛ ‘姻 ‘ (ΗΛ iHO) [6080]
‘ (0Λ iHO) ‘ (ΗΛ iHO) ‘ (3Λ iHO) ‘ (0Λ iHO) ‘(3Λ ‘姻 ‘ (9Λ iHO) ‘ (VA iHO) ‘ (DM ‘33) [8080]
‘(91 ‘33) ‘ (VM ‘33) ‘ (ΖΛ ‘33) ‘ (AA ‘33) ‘ (ΧΛ ‘33) ‘ (Μ ‘33) ‘ (ΛΛ ‘33) ‘ (ΠΛ ‘33) [Ζ.080]
‘ (ΧΛ ‘33) ‘ (SA ‘33) ‘ (Μ ‘33) ‘ (GA ‘33) ‘ (dA ‘33) ‘ (0Λ ‘33) ‘ (NA ‘33) ‘ (嫩 ‘33) [9080]
6 Zn » 6 /-1r\\ 6 /\τ » 6 /~rr\\ ί/Γ» 6 /~rr\\ ί/τ» 6 /~rr\\ ί/ττ» 6 /~rr\\ 6 / r\ » 6 /~rr\\ ί/τ» 6 /~rr\\ 6 / r-1 » L /-rr\\ ΓλλαλΊ
Z9‘ (ΗΛ ‘皿) ‘(3Λ ‘皿) ‘(ΗΛ ‘皿) ‘(3Λ ‘皿) ‘((ΊΛ ‘皿) ‘ Ok ‘皿) ‘(9Λ ‘皿) ‘ (ΥΛ ‘皿) [0960]4 Ol iXH) 4 (91 iXH) ‘ (VI iXH) ‘ (ΖΛ iXH) 4 (AA iXH) ‘ (ΧΛ iXH) ‘ (Μ iXH) ‘ (ΛΛ iXH) [6960]‘ (ΠΛ iXH) ‘ (ΧΛ iXH) ‘ (SA iXH) ‘ (Μ iXH) ‘ (QA iXH) ‘ (dA iXH) ‘ (0Λ iXH) ‘ (NA iXH) [8960]‘ (m iXH) ‘ (ΊΛ iXH) ‘ (Μ iXH) ‘ (ΓΛ iXH) ‘ (ΙΛ iXH) ‘ (ΗΛ iXH) 4 (0Λ iXH) ‘ (ΗΛ iXH) [Z.960]‘ (3Λ iXH) ‘ (ΟΛ iXH) ‘ (3Λ iXH) ‘ (9Λ iXH) 4 (VA iXH) ‘ Ol iSH) ‘ (91 iSH) ‘ (VI iSH) [9960]‘ (ΖΛ iSH) ‘ (ΑΛ iSH) ‘ (ΧΛ iSH) ‘ (Μ iSH) ‘ (ΛΛ iSH) ‘ (ΠΛ iSH) ‘ CLA iSH) ‘ (SA iSH) [9960]‘ (M iSH) ‘ (5Λ iSH) ‘ (dA iSH) ‘ (0Λ iSH) ‘ (NA iSH) ‘(嫩 iSH) ‘(ΊΛ iSH) ‘ (M iSH) [17960]‘ (ΓΛ iSH) ‘ (ΙΛ iSH) ‘ (ΗΛ iSH) ‘ (0Λ iSH) ‘ (ΗΛ iSH) ‘ (3Λ iSH) ‘ (0Λ iSH) ‘ (3Λ iSH) [0960]‘ (9Λ iSH) ‘ (VA iSH) ‘ Ol iHH) ‘ (91 iHH) ‘ (VM iHH) ‘ (ΖΛ iHH) ‘ (AA iHH) ‘ (ΧΛ iHH) [2960]‘ (M iHH) ‘ (ΛΛ iHH) ‘ (ΠΛ iHH) ‘ CLA iHH) ‘ (SA iHH) ‘ (M iHH) ‘ (QA iHH) ‘ (dA iHH) [I960]‘ (0Λ iHH) ‘ (NA iHH) ‘(嫩 iHH) ‘(ΊΛ iHH) ‘ (M iHH) ‘ (ΓΛ iHH) ‘ (ΙΛ iHH) ‘ (ΗΛ iHH) [0960]‘ (0Λ iHH) ‘ (ΗΛ iHH) ‘ (3Λ iHH) ‘ (0Λ iHH) ‘ (DA iHH) ‘ (9Λ iHH) ‘ (VA iHH) ‘ Ol iQH) [61760] ‘ (91 iQH) ‘ (VI iQH) ‘ (ΖΛ iQH) ‘ (AA iQH) ‘ (ΧΛ iQH) ‘ (MA iQH) ‘ (ΛΛ iQH) [81760]‘ (ΠΛ iQH) ‘ (ΧΛ iQH) ‘ (SA iQH) ‘ (Μ iQH) ‘ (QA iQH) ‘ (dA iQH) ‘ (0Λ iQH) ‘ (NA iQH) [Z>60]‘(嫩 iQH) ‘(ΊΛ iQH) ‘ (M iQH) ‘ (ΙΆ ‘δΗ) ‘ (ΙΛ iQH) ‘ (ΗΛ iQH) ‘ (0Λ iQH) ‘ (ΗΛ iQH) [91760]‘ (3Λ iQH) ‘ (0Λ iQH) ‘ 0Λ iQH) ‘ (QA iQH) ‘ (ΥΛ iQH) 4 Ol MH) ‘ (91 MH) ‘ (VI MH) [91760]‘ (ΖΛ MH) ‘(Μ ‘dH) ‘(ΧΛ ‘dH) ‘ (MA MH) ‘ (ΛΛ MH) ‘(M ‘dH) ‘ CLA MH) ‘(SA ‘dH) 01760]‘ (Μ ‘dH) ‘(δΛ ‘dH) ‘(dA ‘dH) ‘(ΟΛ ‘dH) ‘ (NA MH) ‘(嫩 MH) ‘(ΊΛ MH) ‘(M ‘dH) [01760]‘ (ΙΆ ‘dH) ‘(ΙΛ ‘dH) ‘ (ΗΛ MH) ‘(3Λ ‘dH) ‘ (ΗΛ MH) ‘ (3Λ MH) ‘ (ΟΛ ΜΗ) ‘(3Λ ‘dH) [21760] ‘(9Λ ‘dH) ‘ (ΥΛ MH) ‘ (DM iOH) 4 (91 iOH) ‘ (VI iOH) ‘ (ΖΛ ‘OH) ‘ (ΑΛ iOH) [11760]‘ (ΧΛ ‘OH) ‘ (Μ ‘OH) ‘ (ΛΛ ‘OH) ‘ (ΠΛ ‘OH) ‘ (ΧΛ ‘OH) ‘ (SA ‘OH) ‘ (Μ ‘ OH) ‘(δΛ ‘ [01760]OH) 4 (dA iOH) 4 (ΟΛ iOH) 4 (ΝΛ iOH) 4 (ΜΛ iOH) 4 (ΊΛ iOH) 4 (Μ 4 OH) ‘ (ΓΛ iOH) [6060]‘(ΙΛ ‘ΟΗ) ‘ (ΗΛ iOH) ‘ (ΟΛ iOH) ‘ (ΗΛ iOH) ‘ (3Λ iOH) ‘((ΊΛ iOH) ‘(ΟΛ ‘ OH) ‘(9Λ‘ [8060]OH) ‘ (ΥΛ ‘OH) ‘ Ol iNH) ‘ (91 iNH) ‘ (VA iNH) ‘ (ΖΛ iNH) ‘ (Μ ‘ΝΗ) ‘(ΧΛ ‘ΝΗ) [ζ,εβο] ‘ (M iNH) ‘(ΛΛ ‘NH) ‘(Μ ‘NH) ‘ (Μ ‘NH) ‘(SA ‘NH) ‘ (Μ ‘ΝΗ) ‘(δΛ ‘ΝΗ) [9060](dA iNH) ‘(ΟΛ ‘ΝΗ) ‘ (ΝΛ ‘NH) ‘(嫩 iNH) ‘(ΊΛ ‘NH) ‘(Μ ‘NH) ‘ (ΙΆ ‘ΝΗ) ‘(ΙΛ ‘ΝΗ) [9060](ΗΛ iNH) ‘(3Λ ‘ΝΗ) ‘(ΗΛ ‘NH) ‘ (3Λ iNH) ‘((ΊΛ ‘NH) ‘(ΟΛ ‘NH) ‘(9Λ ‘ΝΗ) ‘ (VA iNH) [17060] Ol ‘腿) ‘ (91 ‘腿) ‘ (VM ‘腿) ‘ (ΖΛ ‘腿) ‘ (M ‘腿) ‘(ΧΛ ‘腿) ‘ (Μ ‘腿) [εεβο] (ΛΛ ‘腿) ‘(M ‘腿)‘(M ‘腿)‘(SA ‘腿) ‘(M ‘腿)‘(δΛ ‘腿) ‘(dA ‘腿) [2060] (ΟΛ ‘腿) ‘ (ΝΛ ‘腿) ‘ (NA ‘腿) ‘(ΊΛ ‘腿) ‘(Μ ‘腿) ‘ (ΙΆ ‘腿) ‘(ΙΛ ‘腿) [1060] (ΗΛ ‘腿) ‘(3Λ ‘腿) ‘(ΗΛ ‘腿) ‘ (3Λ ‘腿) ‘((ΊΛ ‘腿) ‘(ΟΛ ‘腿) ‘(9Λ ‘腿) [0060](VA ‘腿) ‘ Ol ‘ΊΗ) ‘ (91 iIH) ‘ (VM iIH) ‘ (ΖΛ iIH) ‘ (ΑΛ iIH) ‘ (ΧΛ ‘ΊΗ) ‘ (M iIH) [6260](ΛΛ ‘ΊΗ) ‘ (ΠΛ ‘ΊΗ) ‘ (ΧΛ iIH) ‘ (SA iIH) ‘ (M iIH) ‘ (δΛ ‘ΊΗ) ‘ (dA ‘ΊΗ) ‘ (0Λ iIH) [8260](ΝΛ ‘ΊΗ) ‘ (Μ ‘ΊΗ) ‘(ΊΛ iIH) ‘ (M iIH) ‘ (ΓΛ iIH) ‘ (ΙΛ ‘ΊΗ) ‘ (ΗΛ ‘ΊΗ) ‘ (0Λ iIH) [Ζ.260](ΗΛ ‘ΊΗ) ‘ (3Λ ‘ΊΗ) ‘ (ΟΛ ‘ΊΗ) ‘ (DA iIH) ‘ (9Λ iIH) ‘ (VA ‘ΊΗ) 4 Ol ‘邪) ‘ (91 ‘邪) [9260](VI ‘邪) ‘ (ΖΛ ‘邪) ‘(Μ ‘邪) ‘(ΧΛ ‘邪) ‘ (MA IH) ‘(ΛΛ ‘邪) ‘(Μ ‘邪) ‘ CLA ‘邪) [9260](SA ‘邪) ‘ (Μ ‘邪) ‘(δΛ ‘邪) ‘(dA ‘邪) ‘(0Λ ‘邪) ‘ (ΝΛ ‘邪) ‘ (Μ ‘ΜΗ) ‘(ΊΛ ‘邪) |>260](Μ ‘邪) ‘ (ΙΆ ‘邪) ‘(ΙΛ ‘邪) ‘ (ΗΛ ‘邪) ‘(3Λ ‘邪) ‘(ΗΛ ‘邪) ‘ (3Λ ‘邪) ‘((ΊΛ ‘邪) [0260]ΟΛ ‘邪) ‘(9Λ ‘邪) ‘ (ΥΛ ‘邪) ‘ (OM ‘ΙΉ) ‘ (91 ‘ΙΉ) ‘ (VI ‘ΙΉ) ‘ (ΖΛ ‘ΙΉ) ‘ (ΑΛ ‘ΙΉ) [2260]X SCI/OSa ZLISZZIOI NO1--10973I——I<s. VN),(Hx, Vs , (Ηχ, Vp),(Ηχ, VQ),(Ηχ, VR),(Ηχ, Vs),(Ηχ, VT),1--10974Ι——Ι<s, (Ηχ, Vv),(Ηχ, Vw),(Ηχ, Vx),(Ηχ, VY),(Ηχ, Vz),(Ηχ, WA),(Ηχ, WB),1--10975Ι——ΙS , (Ηγ, VA),(Ηγ, VB),(Ηγ, Vc),(Ηγ, VD),(Ηγ, VE),(Ηγ, VF),(Ηγ, VG),1--10976Ι——Ι<s. VI),(Ηγ, VJ),(Ηγ, VK),(Ηγ, VL),(Ηγ, VM),(Ηγ, VN),(Ηγ, Vs ,1--10977U <ρ). VQ),(Ηγ, Vs , (Ηγ, Vs),(Ηγ, VT),(Ηγ, Vu),(Ηγ, Vv),(Ηγ, Vw),1--10978Ι——Ι<><). VY),(Ηγ, Vz),(Ηγ, WA),(Ηγ, WB),(Ηγ, Wc),(Hz, VA),(Hz, VB),1--10979Ι——Ι<ο),(Hz, VD),(Hz, VE),(Hz, VF),(Hz, VG),(Hz, VH),(Hz, VI),(Hz, VJ),1--1098S s. <G. s. VL),(Hz, Vs , (Hz, VN),(Hz, Vs , (Hz, Vp),(Hz, VQ),(Hz, VR),(Hz, Vs),(Hz, VT),(Hz, Vu),(Hz, Vv),(Hz, Vw),(Hz, Vx),(Hz, VY),(Hz, Vz),〔0982〕 P WA), P WB), P Wc),
〔0983〕 (ΙΑ, VA),(ΙΑ, VB),(ΙΑ, Vc),(ΙΑ, VD),(ΙΑ, VE),(ΙΑ, VF),(ΙΑ, VG),(ΙΑ, VH),(ΙΑ,νΙ),
〔0984〕 (ΙΑ, VJ), (ΙΑ, VK), (ΙΑ, VL), (ΙΑ, Vs , (ΙΑ, VN), (ΙΑ, Vs , (ΙΑ, Vp), (ΙΑ, VQ),(ΙΑ, VR),
〔0985U (ΙΑ, Vs), (ΙΑ, VT), (ΙΑ, Vs , (ΙΑ, Vv), (ΙΑ, Vw), (ΙΑ, Vx), (ΙΑ, VY), (ΙΑ, Vz),(ΙΑ, WA),
〔0982 (ΙΑ, WB), (ΙΑ, Wc), (IB, VA), (IB, VB), (IB, Vc), (IB, VD), (IB, Vm), (IB, VF),(IB, VG),
〔0987U (IB, VH),(IB, VI),(IB, VJ),(IB, VK),(IB, VL),(IB, VM),(IB, VN),(IB, Vs ,(IB, Vp),
〔0988〕 (IB, VQ), (IB, VR), (IB, Vs), (IB, VT), (IB, Vs , (IB, Vv), (IB, Vw), (IB, Vx),(IB, VY),
toCDooCDu (IB, Vz), (IB, WA), (IB, WB), (IB, Wc), (IP VA), (IP VA), (IP VB), (IP VB),
αρVc),
〔0990〕 αρVD),αρVE),αρVF),αρVG),αρVH),αρVI),αρVJ),αρVK),
αρS,
〔0991〕 (IP Vs , (IP VN),(IP Vs , (IP Vp),(IP VQ),(IP VR),(IP Vs),(IP VT),
58
19‘ (3Λ iZI) ‘ (αΛ iZi) ‘ (ΟΛ ‘ZI) ‘ (9Λ iZI) ‘ (ΥΛ ‘ZI) ‘ (DM iAI) ‘ (SM iAI) ‘ (VM iAI) [Ζ.901 ‘ (ΖΛ ‘入I‘ (ΑΛ iAI) ‘ (ΧΛ iAI) ‘ (MA iAI) ‘ (ΛΛ iAI) ‘ (ΠΛ iAI) ‘(ΧΛ iAI) 4 (SA iAI) ‘ (Μ iAI) [9901 ‘ (δΛ iAI) ‘ (dA iAI) ‘ (ΟΛ iAI) ‘ (ΝΛ iAI) ‘ (ΊΛ iAI) 4(ΓΛ iAI) iQAiAI) [9901 ‘ (ΗΛ ‘入I‘ (0Λ iAI) ‘ (dA iAI) ‘ (3A iAI) ‘ (ΟΛ iAI) ‘ (ΟΛ ‘入I) ‘(QA iAI) ‘(ΥΛ iAI) ‘ (OM ‘XI) [17901 ‘ (ai ‘χι‘ (VI ‘XI) ‘ (ΖΛ ‘XI) ‘ (AA ‘XI) ‘ (ΧΛ ‘XI) ‘ (Μ ‘XI) ‘(ΛΛ ‘XI) ‘ (Μ ‘XI) ‘ (ΧΛ ‘XI) [0901 ‘ (SA ‘XI‘ (Μ ‘XI) ‘ (δΛ ‘XI) ‘ (dA ‘XI) ‘ (ΟΛ ‘XI) ‘ (ΝΛ ‘XI) ‘ (Μ ‘XI) ‘CU ‘XI) ‘ (Μ ‘XI) [2901 ‘ (ΓΛ ‘XI‘ (ΙΛ ‘XI) ‘ (ΗΛ ‘XI) ‘ (0Λ ‘XI) ‘ (dA ‘XI) ‘ (3Λ ‘XI) ‘ (αΛ ‘χι) ‘ (3Λ ‘XI) ‘ (9Λ ‘XI) [1901‘ (VA ‘XI) ‘ (OM ‘II) ‘ (91 ‘II) ‘ (VM ‘II) ‘ (ΖΛ ‘II) ‘ (ΑΑ iMI) ‘(ΧΛ ‘II) ‘ (Μ ‘II) [0901‘ (ΛΛ ‘II) ‘ (ΠΛ ‘II) ‘ CLA ‘II) ‘ (SA ‘II) ‘ (Μ ‘II) ‘ (5Λ ‘II) iCdA ‘II) ‘ (ΟΛ ‘II) [6901‘ (NA ‘II) ‘ (Μ ‘II) ‘ (ΊΛ ‘II) ‘ (M ‘II) ‘ (ΓΛ ‘II) ‘(ΙΛ ‘II) ‘(ΗΛ ‘II) ‘ (ΟΛ ‘II) [8901‘ (ΗΛ ‘II) ‘ (3Λ ‘II) ‘ (0Λ ‘II) ‘ (OA ‘II) ‘ (9Λ ‘II) ‘ (VA ‘II) ‘ (DA iAI) ‘ (QM ‘Al) [Z.901 ‘ (VI ‘ΛΙ‘ (ΖΛ ‘Al) ‘ (AA iAI) ‘ (ΧΛ ‘Al) ‘ (MA ‘Al) (ΛΛ ‘Al) ‘(ΠΛ ‘Al) iUA iAI) ‘ (SA ‘Al) [9901 ‘ (Μ ‘ΛΙ‘(δΛ ‘Al) ‘ (dA ‘Al) ‘ (ΟΛ ‘Al) ‘ (MA ‘Al) ‘ (ΜΛ ‘Al) ‘(ΊΛ ‘Al) ‘(Μ ‘Al) ‘ (ΓΛ ‘Al) [9901 ‘ (ΙΛ ‘ΛΙ‘ (ΗΛ ‘Al) ‘ (0Λ ‘Al) ‘ (dA ‘Al) ‘ (3A ‘Al) ‘ (ΟΛ ‘Al) ‘(OA ‘Al) ‘(9Λ iAI) ‘ (VA ‘Al) [17901‘ (OM ‘ηι) ‘ (ai ‘ηι) ‘ (VM ‘ηι) ‘ (ζλ ‘ηι) ‘ (ΑΑ ‘ηι) ‘ (χλ ‘ηι) ‘ (Μ ‘ηι) ‘ (λλ ‘ηι) [0901‘ (πλ ‘ηι) ‘ (χλ ‘ηι) ‘ (sa ‘ηι) ‘ (μ ‘ηι) ‘ (δΛ ‘ηι) ‘ (dA ‘ηι) ‘(ΟΛ ‘ηι) ‘ (νλ ‘ηι) [2901‘ (μ ‘ηι) ‘ (ΊΛ ‘ηι) ‘ (μ ‘ηι) ‘ (Γλ ‘ηι) ‘(ιλ ‘ηι) ‘ (ΗΛ ‘ηι) ‘ (Ok ‘ηι) ‘ (dA ‘ηι) [1901 ‘ (3Λ ‘ηι‘ (αΛ ‘ηι) ‘ (ΟΛ ‘ηι) ‘ (9Λ ‘ηι) ‘ (VA ‘ηι) ‘ (DM iXI) ‘ (91 iXI) ‘(VI iXI) ‘ (ΖΛ iXI) [0901 ‘ (ΑΛ iXI‘ (ΧΛ iXI) ‘ (MA iXI) ‘ (ΛΛ iXI) ‘ (ΠΛ iXI) ‘ CLA ‘11) 4(SA iXI) ‘(Μ iXI) ‘ (5Λ iXI) [61701 ‘ (dA iXI‘ (0Λ iXI) ‘ (NA iXI) ‘ (Μ iXI) ‘ (ΊΛ ‘U) ‘ (Μ iXI) ‘(ΓΛ iXI) ‘(ΙΛ iXI) ‘ (ΗΛ iXI) [81701 ‘ (0Λ iXI‘ (dA iXI) ‘ (3A iXI) ‘ (αΛ iXi) ‘ (3Λ ‘U) ‘ (9Λ iXI) ‘(ΥΛ iXI) ‘ Oi ‘SI) ‘ (ai ‘Si) [Z.1701 ‘ (VI ‘SI‘ (ΖΛ ‘SI) ‘ (AA ‘SI) ‘ (ΧΛ ‘SI) ‘ (Μ ‘SI) ‘ (ΛΛ ‘SI) ‘(ΠΛ ‘SI) ‘(Μ ‘SI) ‘ (SA ‘SI) [91701 ‘ (M ‘SI‘(δΛ ‘SI) ‘ (dA ‘SI) ‘ (ΟΛ ‘SI) ‘ (ΝΛ ‘SI) ‘ (ΜΛ ‘SI) ‘Cu ‘Si) ‘(Μ ‘SI) 4(ΓΛ ‘SI) [91701 ‘(ΙΛ‘SI‘ (ΗΛ ‘SI) ‘ (0Λ ‘SI) ‘ (dA ‘SI) ‘ (ΞΑ ‘SI) ‘ (αΛ ‘Si) ‘(OA ‘SI) ‘(9Λ ‘SI) ‘ (ΥΛ ‘SI) OwnX SCIAS O ZL18ZZ101 NO
[1162] (JZ,VX),(JZ,VY),(JZ,VZ),(JZ,WA),(JZ,WB),(JZ,WC),
[1163] (KA, VA),(KA, VB),(KA, VC),(KA, VD),(KA, VE),(KA, VF),(KA, VG),(KA, VH),
[1164] (KA, VI),(KA, VJ),(KA, VK),(KA, VL),(KA, VM),(KA, VN),(KA, VO),(KA, VP),
[1165] (KA, VQ),(KA, VR),(KA, VS),(KA, VT),(KA, VU),(KA, VV),(KA, Vff),(KA, VX),
[1166] (KA, VY),(KA, VZ),(KA, WA),(KA, WB),(KA, WC),(KB, VA),(KB, VB),(KB, VC),
[1167] (KB, VD),(KB, YE),(KB, VF),(KB, VG),(KB, VH),(KB, VI),(KB, VJ),(KB, VK),
[1168] (KB, VL),(KB, VM),(KB, VN),(KB, VO),(KB, VP),(KB, VQ),(KB, VR),(KB, VS),
[1169] (KB, VT),(KB, VU),(KB, VV),(KB, Vff),(KB, VX),(KB, VY),(KB, VZ),(KB, WA),
[1170] (KB, WB),(KB, WC),(KC, VA),(KC, VA),(KC, VB),(KC, VB),(KC, VC),(KC, VD),
[1171] (KC, VE),(KC, VF),(KC, VG),(KC, VH),(KC, VI),(KC, VJ),(KC, VK),(KC, VL),
[1172] (KC, VM),(KC, VN),(KC, VO),(KC, VP),(KC, VQ),(KC, VR),(KC, VS),(KC, VT),
[1173] (KC, VU),(KC, VV),(KC, Vff),(KC, VX),(KC, VY),(KC, VZ),(KC, WA),(KC, WB),
[1174] (KC, WC),(KD, VC),(KD, VD),(KD, VE),(KD, VF),(KD, VG),(KD, VH),(KD, VI),
[1175] (KD, VJ),(KD, VK),(KD, VL),(KD, VM),(KD, VN),(KD, VO),(KD, VP),(KD, VQ),
[1176] (KD, VR),(KD, VS),(KD, VT),(KD, VU),(KD, VV),(KD, Vff),(KD, VX),(KD, VY),
[1177] (KD, VZ),(KD, WA),(KD, WB),(KD, WC),(KE, VA),(KE, VB),(KE, VC),(KE, VD),
[1178] (KE, VE),(KE, VF),(KE, VG),(KE, VH),(KE, VI),(KE, VJ),(KE, VK),(KE, VL),
[1179] (KE, VM),(KE, VN),(KE, VO),(KE, VP),(KE, VQ),(KE, VR),(KE, VS),(KE, VT),
[1180] (KE, VU),(KE, VV),(KE, Vff),(KE, VX),(KE, VY),(KE, VZ),(KE, WA),(KE, WB),
[1181] (KE, WC),(KF, VA),(KF, VB),(KF, VC),(KF, VD),(KF, VE),(KF, VF),(KF, VG),
[1182] (KF, VH),(KF, VI),(KF, VJ),(KF, VK),(KF, VL),(KF, VM),(KF, VN),(KF, VO),
[1183] (KF, VP),(KF, VQ),(KF, VR),(KF, VS),(KF, VT),(KF, VU),(KF, VV),(KF, Vff),
[1184] (KF, VX),(KF, VY),(KF, VZ),(KF, WA),(KF, WB),(KF, WC),(KG, VA),(KG, VB),
[1185] (KG, VC),(KG, VD),(KG, VE),(KG, VF),(KG, VG),(KG, VH),(KG, VI),(KG, VJ),
[1186] (KG, VK),(KG, VL),(KG, VM),(KG, VN),(KG, VO),(KG, VP),(KG, VQ),(KG, VR),
[1187] (KG, VS),(KG, VT),(KG, VU),(KG, VV),(KG, Vff),(KG, VX),(KG, VY),(KG, VZ),
[1188] (KG, WA),(KG, WB),(KG, WC),(KH, VA),(KH, VB),(KH, VC),(KH, VD),(KH, VE),
[1189] (KH, VF),(KH, VG),(KH, VH),(KH, VI),(KH, VJ),(KH, VK),(KH, VL),(KH, VM),
[1190] (KH, VN),(KH, VO),(KH, VP),(KH, VQ),(KH, VR),(KH, VS),(KH, VT),(KH, VU),
[1191] (KH, VV),(KH, Vff),(KH, VX),(KH, VY),(KH, VZ),(KH, WA),(KH, WB),
[1192] (KH, WC),(KI, VA),(KI, VB),(KI, VC),(KI, VD),(KI, VE),(KI, VF),(KI, VG),
[1193] (KI, VH),(KI, VI),(KI, VJ),(KI, VK),(KI, VL),(KI, VM),(KI, VN),(KI, VO), (KI, VP),
[1194] (KI,VQ),(KI,VR),(KI,VS),(KI,VT),(KI,VU),(KI,VV),(KI,Vff),(KI,VX),
[1195] (KI,VY),(KI,VZ),(KI,WA),(KI,WB),(KI,WC),(KJ,VA),(KJ,VB),(KJ,VC),
[1196] (KJ, VD),(KJ, VE),(KJ, VF),(KJ, VG),(KJ, VH),(KJ, VI),(KJ, VJ),(KJ, VK),
[1197] (KJ, VL),(KJ, VM),(KJ, VN),(KJ, VO),(KJ, VP),(KJ, VQ),(KJ, VR),(KJ, VS),
[1198] (KJ, VT),(KJ, VU),(KJ, VV),(KJ, Vff),(KJ, VX),(KJ, VY),(KJ, VZ),(KJ, WA),
[1199] (KJ, WB),(KJ, WC),(KK, VA),(KK, VB),(KK, VC),(KK, VD),(KK, VE),(KK, VF),yy
‘ (λλ ‘mo ‘ (πλ ‘mo ‘ (χλ ‘mo ‘ (sa ‘mo ‘ (μ ‘mo ‘ (Ga ‘mo ‘ (dh ‘mo ‘ (ολ ‘mo [8021]
‘ (νλ ‘η)0 ‘ (μλ ‘η)0 ‘ (ίλ ‘η® ‘ (μ ‘η® ‘ (Γλ ‘η® ‘ (ιλ ‘η® ‘ (ηλ ‘η® ‘ (ολ ‘mo [lzz\.~\
‘ (ηλ ‘mo ‘ (3Λ ‘mo ‘(<ίλ ‘mo ‘ ολ ‘mo ‘ (9Λ ‘mo ‘ (va ‘mo ‘ Oi ‘υ) ‘ (ai ‘u) [9021]
‘ (VI ‘U) ‘ (ΖΛ ‘U) ‘ (ΑΛ ‘U) ‘ (ΧΛ ‘U) ‘ (Μ ‘U) ‘ (ΛΛ ‘U) ‘ (ΠΛ ‘U) ‘ (ΧΛ ‘U) [9021]
‘ (SA ‘U) ‘ (ΗΛ ‘U) ‘ (GA ‘U) ‘ (dA ‘U) ‘ (ΟΛ ‘U) ‘ (ΝΛ ‘U) ‘ (ΜΛ ‘U) ‘ (ΊΛ ‘U) [nzi]
‘ (Μ ‘U) ‘ (ΓΛ ‘U) ‘ (ΙΛ ‘U) ‘ (ΗΛ ‘U) ‘ (ΟΛ ‘U) ‘ (ΗΛ ‘U) ‘ (3Λ ‘U) ‘((ΊΛ ‘U) [0021]
‘ (ΟΛ ‘U) ‘ (9Λ ‘U) ‘ (VA ‘U) ‘ Ol ‘SM) ‘(91 ‘SM) ‘ (VI ‘SM) ‘ (ΖΛ ‘SM) ‘ (ΑΛ ‘SM) [2021]
‘ (ΧΛ ‘SM) ‘ (Μ ‘SM) ‘ (ΛΛ ‘SM) ‘ (ΠΛ ‘SM) ‘ (ΧΛ ‘SM) ‘ (SA ‘SM) ‘ (ΗΛ ‘SM) ‘ (GA ‘SM) [1021]
‘ (dA ‘SM) ‘ (0Λ ‘SM) ‘ (NA ‘SM) ‘ (ΜΛ ‘SM) ‘ (ΊΛ ‘SM) ‘ (M ‘SM) ‘ (ΓΛ ‘SM) ‘ (ΙΛ ‘SM) [0021]
‘ (ΗΛ ‘SM) ‘ (0Λ ‘SM) ‘ (ΗΛ ‘SM) ‘ (3Λ ‘SM) ‘ (0Λ ‘SM) ‘ (3Λ ‘SM) ‘ (9Λ ‘SM) ‘ (VA ‘SM) [6221]
‘ Ol iM) ‘ (91 iM) ‘ (VI iM) ‘ (ΖΛ iM) ‘ (ΑΛ iM) ‘ (ΧΛ iM) ‘ (M iM) ‘ (ΛΛ iM) [8221]
‘ (ΠΛ iM) ‘ CLA iM) ‘ (SA iM) ‘ (ΗΛ iM) ‘ (GA iM) ‘ (dA iM) ‘ (0Λ iM) ‘ (NA iM) [Z.221]
‘ (ΜΛ iM) ‘ (ΊΛ iM) ‘ (M iM) ‘ (ΓΛ iM) ‘ (ΙΛ iM) ‘ (ΗΛ iM) ‘ (0Λ iM) ‘ (ΗΛ iM) [9221]
‘ (3Λ iM) ‘ (0Λ iM) ‘ (DA iM) ‘ (9Λ iM) ‘ (VA iM) ‘ (DM iQM) ‘ (91 iQM) ‘ (VM iQM) [9221]
‘ (ΖΛ ‘δ)0 ‘ (ΑΑ ‘δ)0 ‘ (ΧΛ ‘δ)0 ‘ (MA ‘δ)0 ‘ (ΛΛ ‘δ)0 ‘ (ΠΛ ‘δ)0 ‘ (ΧΛ ‘δ)0 ‘ (SA ‘δ)0 [^2l]
‘ (μ ‘δ® ‘ (δΛ ‘δ® ‘ (dA ‘δ® ‘ (ολ ‘δ® ‘ (νλ ‘δ® ‘ (μ ‘δ® ‘ (ίλ ‘δ® ‘ (μ ‘δ® [ε22ΐ]
‘ (Γλ ‘δ® ‘ (ιλ ‘δ® ‘ (ηλ ‘δ® ‘ (ολ ‘δ® ‘ (αα ‘δ® ‘ (ξα ‘δ® ‘ (ολ ‘δ® ‘ (da ‘δ® [2221]
‘ (9Λ ‘δ® ‘ (va ‘δ® ‘ (dm ‘d)0 ‘ (ai ‘d® ‘ (vm ‘d® ‘ (ζλ ‘d)0 ‘ (aa ‘d® ‘ (χλ ‘d)0 [1221]
‘ (M ‘d)0 ‘ (ΛΛ ‘d)0 ‘ (ΠΛ ‘d)0 ‘ (ΧΛ ‘d)0 ‘ (SA ‘d® ‘ (M ‘d® ‘ (GA ‘d® ‘ (dA ‘d® [0221]
‘ (ΟΛ ‘d)0 ‘ (NA ‘d)0 ‘ (ΜΛ ‘d)0 ‘ (ΊΛ ‘d® ‘ (M ‘d® ‘ (ΓΛ ‘d® ‘ (ΙΛ ‘d® ‘ (ΗΛ ‘d® [6121]
‘ (ΟΛ ‘d)0 ‘ (ΗΛ ‘d)0 ‘ (3Λ ‘d)0 ‘((ΊΛ ‘d)0 ‘ (DA ‘d® ‘ (9Λ ‘d® ‘ (VA ‘d® ‘ (DM ‘0 [8121]
)0 ‘(91 ‘0)0 ‘ (VM ‘0)0 ‘ (ΖΛ ‘0)0 ‘ (AA ‘0)0 ‘ (ΧΛ ‘0)0 ‘ (MA ‘0)0 ‘ (ΛΛ ‘0 [Ζ.121]
)0 ‘ (ΠΛ ‘0)0 ‘ (JA ‘0)0 ‘ (SA ‘0)0 ‘ (ΗΛ ‘0)0 ‘ (GA ‘0)0 ‘ (dA ‘0)0 ‘ (0Λ ‘0)0 [9121]
‘ (NA ‘0)0 ‘ (ΜΛ ‘0)0 ‘ (ΊΛ ‘0)0 ‘ (M ‘0)0 ‘ (ΓΛ ‘0)0 ‘ (ΙΛ ‘0)0 ‘ (ΗΛ ‘0)0 ‘ (0Λ ‘0 [9121]
)0 ‘ (ΗΛ ‘0)0 ‘ (3Λ ‘0)0 ‘ (0Λ ‘0)0 ‘ (DA ‘0)0 ‘ (9Λ ‘0)0 ‘ (VA ‘0)0 ‘ (DM iNM) [W2l·]
‘ (91 ‘■) ‘ (VM ‘■) ‘(ΖΛ ‘■) ‘ (AA ‘■) ‘ (ΧΛ ‘■) ‘ (MA ‘■) ‘ (ΛΛ ‘■) ‘ (ΠΛ ‘■) [0121]
‘ (ΧΛ ‘■) ‘ (SA ‘■) ‘ (Μ ‘■) ‘(GA ‘■) ‘ (dA ‘■) ‘ (0Λ ‘■) ‘ (NA ‘■) ‘ (嫩 ‘■) [2121]
‘ (ΊΛ ‘■) ‘ (Μ ‘■) ‘ (ΓΛ ‘■) ‘(ΙΛ ‘■) ‘ (ΗΛ ‘■) ‘ (ΟΛ ‘■) ‘ (ΗΛ ‘■) ‘ (3Λ ‘■) [U21]
‘((ΊΛ ‘■) ‘(ΟΛ ‘■) ‘ (9Λ ‘■) ‘ (VA ‘■) ‘ (DM ‘圆)‘ (91 ‘圆)‘ (VM ‘圆)[0121]
‘(ΖΛ ‘圆)‘ (AA ‘圆)‘ (ΧΛ ‘圆)‘ (MA ‘圆)‘ (ΛΛ ‘圆)‘ (ΠΛ ‘圆)‘ (JA ‘圆) [6021]
‘ (SA ‘圆)‘ (Μ ‘圆)‘ (GA ‘圆)‘ (dA ‘圆)‘ (ΟΛ ‘圆)‘ (NA ‘圆)‘(嫩‘圆)[8021]
‘ (ΊΛ ‘圆)‘ (Μ ‘圆)‘ (ΓΛ ‘圆)‘(ΙΛ ‘圆)‘ (ΗΛ ‘圆)‘ (ΟΛ ‘圆)‘ (ΗΛ ‘圆)‘ (3Λ ‘圆) [順]
‘((ΊΛ iM) ‘ ΟΛ iM) ‘ (9Λ iM) ‘ (VA iM) ‘ (31 ‘Ί)0 ‘ (91 ‘Ί)0 ‘ (VI ‘Ί)0 ‘ (ΖΛ ‘Ί)0 [9021]
‘ (ΑΛ ‘Ί)0 ‘ (ΧΛ ‘Ί)0 ‘ (Μ ‘Ί)0 ‘ (ΛΛ ‘Ί)0 ‘ (ΠΛ ‘Ί)0 ‘ (ΧΛ ‘Ί)0 ‘ (SA ‘Ί)0 ‘ (ΗΛ ‘Ί)0 [9021]
‘ (GA ‘Ί)0 ‘ (dA ‘Ί)0 ‘ (ΟΛ ‘Ί)0 ‘ (ΝΛ ‘Ί)0 ‘ (ΜΛ ‘Ί)0 ‘ (ΊΛ ‘Ί)0 ‘ (Μ ‘Ί)0 ‘ (ΓΛ ‘Ί)0
‘ (ΙΛ ‘Ί)0 ‘ (ΗΛ ‘Ί)0 ‘ (ΟΛ ‘Ί)0 ‘ (ΗΛ ‘Ί)0 ‘ (3Λ ‘Ί)0 ‘((ΊΛ ‘Ί)0 ‘ (ΟΛ ‘Ί)0 ‘ (9Λ ‘Ί)0 [0021]
‘ (VA ‘Ί)0 ‘ Ol iM) ‘ (91 iM) ‘ (VI iM) ‘(ΖΛ ‘)Η) ‘ (ΑΛ iM) ‘ (ΧΛ iM) ‘ (M iM) [2021]
‘ (ΛΛ ‘观 ‘ (ΠΛ ‘观 ‘ (JA ‘观 ‘ (SA ‘观 ‘ (Μ ‘观 ‘ (GA ‘观 ‘ (dA ‘观 ‘ (0Λ ‘观 [1021]
6 /κ τ » 6 λτλτΝ 6 /tit » 6 λτλτΝ 6 /n » 6 λτλτΝ 6 /\τ » 6 λτλτΝ 6 /P» 6 λτλτΝ 6 /τ» 6 λτλτΝ 6 /τ τ » 6 λτλτΝ 6 Zrw 6 λτλτΝ Γλλ~»·Ί
[1388] (MJ, VC),(MJ, VD),(MJ, VE),(MJ, VF),(MJ, VG),(MJ, VH),(MJ, VI),(MJ, VJ),
[1389] (MJ, VK),(MJ, VL),(MJ, VM),(MJ, VN),(MJ, VO),(MJ, VP),(MJ, VQ),(MJ, VR),
[1390] (MJ, VS),(MJ, VT),(MJ, VU),(MJ, VV),(MJ, Vff),(MJ, VX),(MJ, VY),(MJ, VZ),
[1391] (MJ, WA),(MJ, WB),(MJ, WC),(MK, VA),(MK, VB),(MK, VC),(MK, VD),
[1392] (MK, VE),(MK, VF),(MK, VG),(MK, VH),(MK, VI),(MK, VJ),(MK, VK),(MK, VL),
[1393] (MK, VM),(MK, VN),(MK, VO),(MK, VP),(MK, VQ),(MK, VR),(MK, VS),
[1394] (MK, VT),(MK, VU),(MK, VV),(MK, Vff),(MK, VX),(MK, VY),(MK, VZ),
[1395] (MK, WA),(MK, WB),(MK, WC),(ML, VA),(ML, VB),(ML, VC),(ML, VD),
[1396] (ML, VE),(ML, VF),(ML, VG),(ML, VH),(ML, VI),(ML, VJ),(ML, VK),(ML, VL),
[1397] (ML, VM),(ML, VN),(ML, VO),(ML, VP),(ML, VQ),(ML, VR),(ML, VS),(ML, VT),
[1398] (ML, VU),(ML, VV),(ML, Vff),(ML, VX),(ML, VY),(ML, VZ),(ML, WA),(ML, WB),
[1399] (ML, WC),(MM,VA),(MM,VB),(MM,VC),(MM,VD),(MM,VE),(MM,VF),
[1400] (MM, VG),(MM, VH),(MM, VI),(MM, VJ),(MM, VK),(MM, VL),(MM, VM),
[1401] (MM,VN),(MM,VO),(MM,VP),(MM,VQ),(MM,VR),(MM,VS),(MM,VT),
[1402] (MM, VU),(MM, VV),(MM, Vff),(MM, VX),(MM, VY),(MM, VZ),(MM, WA),
[1403] (MM,WB),(MM,WC),(MN,VA),(MN,VB),(MN,VC),(MN,VD),(MN,VE),
[1404] (MN, VF),(MN, VG),(MN, VH),(MN, VI),(MN, VJ),(MN, VK),(MN, VL),
[1405] (MN,VM),(MN,VN),(MN,VO),(MN,VP),(MN,VQ),(MN,VR),(MN,VS),
[1406] (MN,VT),(MN,VU),(MN,VV),(MN,Vff),(MN,VX),(MN,VY),(MN,VZ),
[1407] (MN, WA),(MN, WB),(MN, WC)
[1408] 本文使用的“发呕、呕吐和/或便秘”包括因摄取具有阿片样物质受体(尤其是阿片样物质受体)激动活性的化合物引起的恶心、发呕、呕吐和/或便秘。具体地说,“具有阿片样物质受体激动活性的化合物”的例子包括吗啉、羟考酮、芬太尼、美沙酮、可待因、二氢可待因、氢吗啡酮、左啡诺、哌替啶、右丙氧芬、右旋丙氧吩、曲马多和它们的药物可接受的盐或溶剂化物。特别地,当化合物为吗啉、羟考酮或它们的药物可接受的盐或溶剂化物时,本发明的化合物尤其有效。
[1409] 例如,可通过下面的试验证实本发明的化合物对发呕或呕吐的影响。
[1410] 在摄取饮食后30分钟时,为雪貂给药每种试 验物质。将试验化合物溶解在5%木糖醇中,并以5mg/kg给药。在给药试验化合物后30分钟时,皮下给药O. 6mg/kg的吗啉,直到给药吗啉后30分钟时才目视观察到呕吐症状。
[1411] 对于每种发呕(腹部处的节律性收缩运动)和呕吐(排泄呕吐物的呕吐行为或类似行为),收集出现时间、潜伏时间(从给药吗啉到开始出现呕吐症状的时间)和持续时间(从开始呕吐到最后呕吐的时间)。
[1412] 另外,例如,通过下面的试验证实本发明的化合物对便秘的影响。
[1413] I)试验饮食(染料)的制备
[1414] 使用O. 5w/v%伊文思(Evans)蓝水溶液,制备2. 5w/v%羧甲基纤维素盐溶液,并使用它作为试验饮食。
[1415] 2)动物
[1416] 例如,可使用Wistar雄性大鼠(6_7周龄)。在试验开始前使动物禁食约20或更多个小时,并随意地给予水。[1417] 3)试验化合物和介质[1418] 将试验化合物溶解在溶剂(DMAA/Solutol/5%甲基葡胺=15/15/70)中。[1419] DMAA :N,N-二甲基乙酰胺[1420] Solutol (注册商标)HS15[1421] 甲基葡胺:D(-)_N-甲基葡糖胺[1422] 将盐酸吗啉溶解在生理盐水中。[1423] 试验化合物、溶剂和吗啉都以2mL/kg的液体量给药。[1424] 4)方法[1425] 皮下给药试验化合物O. 03、O.1、O. 3、I或3mg/kg(试验化合物给药组)或溶剂(溶剂给药组),并在75分钟后对所有组皮下给药3mg/kg数量的吗啉。作为对照组,皮下给药溶剂,并在75分钟后给药生理药水。[1426] 在给药吗啉后30分钟时口服给药试验饮食2mL/大鼠。在试验饮食后15分钟时 (在试验物质给药后120分钟时),从食道到靠近胃贲门部位的回肠盲肠部位分离大鼠。测量从胃幽门部位到回肠盲肠部位的距离(小肠的完整长度)和直到染料到达前端部位的距离(染料移动距离)。[1427] 5)数据处理[1428] 转运率(% )=(染料移动距离(cm)) /小肠的完整长度(cm)) X 100M. P. E. (% ) =K试验化合物给药组每个个体的小肠转运率(%)_溶剂给药组的平均小肠转运率 (% ))/(对照组的平均小肠转运率)-溶剂给药组的平均小肠转运率(% ))} Xioo[1429] 通过使用% MPE并设置对照组的值为100%回归SAS程序的逆向估计计算ED5tl值。[1430] 本发明的化合物具有阿片样物质受体(尤其是阿片样物质δ和μ受体)拮抗活性。因此,除了由具有阿片样物质受体激动活性的化合物引起的发呕•呕吐•便秘外,本发明的化合物能有效治疗和/或预防由以下原因引起的消化道疾病,所述原因如急性消化不良、急性酒精中毒、食物中毒、感冒、胃溃疡、十二指肠溃疡、胃癌、肠梗阻、阑尾炎、腹膜炎、 胆石病、肝炎、肝的炎症、脑炎、脑膜炎、脑压升高、头外伤、运动病、妊娠呕吐、化疗引起的副作用、辐射治疗引起的副作用、抗癌药引起的副作用、消化道的压迫 ·狭窄和手术后肠道结合,治疗和/或预防由以下原因引起的发呕和呕吐,原因如脑肿瘤•脑出血·脑膜炎•用射线辐射脑引起的脑压升高,和治疗和/或预防源于如下原因如肠梗阻、十二指肠溃疡或阑尾炎的急性便秘、源于原因如神经疾病、营养不良、一般性衰竭、维生素缺乏、贫血、敏感性下降或机械性刺激不充分引起的缓和性便秘,或源于原因如应激的痉挛性便秘。[1431] 由于本发明的化合物具有低的脑转变(brain transition),因此它表现出对副作用如因阿片样物质受体激动活性引起的发呕、呕吐、便秘等的高减轻作用,几乎不抑制给药到患者的具有阿片样物质受体激动活性的化合物的止痛活性,并伴随疼痛减少(例如,癌疼痛(骨转化、神经压力、头颅内压力升高、软组织浸润引起的疼痛,便秘或肌肉痉挛引起的疼痛,内脏、肌肉、筋膜、腰或肩关节外围的疼痛,手术后慢性疼痛)、AIDS等)。另外,本发明的化合物对阿片样物质受体具有纯的拮抗活性,还具有安全优势,hERG通道抑制活性低,没有心脏毒性等。此外,本发明的化合物在身体内的动力学方面还具有有利特点,如高的口服吸收性、在人血浆中的高稳定性、高的生物利用度等,并且作为药物非常有效。[1432]当给药本发明的化合物抵抗由具有阿片样物质受体激动活性的化合物引起的发呕、呕吐或便秘时,给药可在具有阿片样物质受体激动活性的化合物的给药之前、之后或同时中的任何一个。对这两种药物之间的给药间隔没有特殊限制。例如,当在具有阿片样物质受体激动活性的化合物的给药之后给药本发明的化合物时,如果随后立即给药或在约3天内给药,且优选从具有阿片样物质受体激动活性的化合物的给药开始随后立即给药或在约I天内给药的话,则本发明的化合物能更有效地发挥作用。另外,当在具有阿片样物质受体激动活性的化合物的给药之前给药本发明的化合物时,如果在恰好开始前或约I天前给药,优选从具有阿片样物质受体激动活性的化合物的给药开始恰好之前或约12小时前的话,则本发明的化合物更有效地发挥作用。
[1433] 当本发明的化合物作为治疗和/或预防发呕、呕吐和/或便秘的药剂被给药时,它可与治疗和/或预防发呕、呕吐和/或便秘的其它药剂结合使用。例如,可以与以下药物结合给予药剂:盐酸恩丹西酮(ondansetrone)、肾上腺皮质留醇(甲基强的松龙、强的松龙、地塞米松等)、丙氯拉嗪、氟哌唳醇、thymiperone、奋乃静、灭吐灵、多潘立酮、东莨菪碱、盐酸氯丙嗪、氟哌利多、刺激性轻泻剂(番泻苷、匹可硫酸钠等)、渗透性轻泻剂(乳果糖等)或盐类轻泻剂(氧化镁等)。
[1434] 或者,可给药本发明的化合物和具有阿片样物质受体激动活性的化合物之间的联合药剂,或本发明的化合物和治疗和/或预防发呕、呕吐和/或便秘的其它药剂之间的联合药剂。
[1435] 当本发明的化合物被给药于人时,可作为粉剂、颗粒剂、片剂、胶囊、药丸、溶液等口服给药,或作为注射剂、栓剂、经皮吸收剂、吸收剂等肠胃外给药。口服药剂是优选的。
[1436] 另外,可通过加入适合配方的药物添加剂如赋形剂、粘合剂、润湿剂、崩解剂、润滑剂等和有效量的本发明化合物将本发明化合物配制成药物制剂。
[1437] 本发明的化合物可被配制成药物混合物,包含具有阿片样物质受体激动活性的化合物和/或治疗和/或预防发 呕、呕吐和/或便秘的其它药剂,需要时,包含各种药物添加剂。
[1438] 剂量根据疾病状态、给药途径、患者的年龄和体重而不同,当口服给药于成人时,通常为O.1 μ g-lg/天,优选O. 01-200mg/天,当肠胃外给药时,通常为O.1 μ g-10g/天,优选 O. l-2g/ 天。
[1439] 下面的实施例和试验实施例更详细地说明本发明,但本发明不受这些实施例限制。
[1440][实施例1]
[1441] 化合物(1-4)的制备
[1442][化学式 11]
[1443]
Π-4)[1444] 其中Bn代表苄基,Et代表乙基,Pri代表异丙基。[1445](第一个步骤)7-乙氧基羰基纳曲酮[1446] 向非专利文献2中描述的3-0-苄基-7-乙氧基羰基纳曲酮(11. 16g,22. 15mmol) 在乙酸乙酯(50mL)和甲醇(50mL)中的悬浮液中加入氢氧化IE (Perlman催化剂)(1. 2g), 并在氢气气氛下强烈搅拌混合物2小时。在过滤催化剂后,浓缩滤液,由乙酸乙酯和己烷结晶残余物得到8. 96g(92% )标题化合物,为无色晶体。[1447] NMR (300MHz, CDCl3) δ O. 14-0. 17(m,2H),0· 55-0. 58 (m, 2Η),0· 86 (m, ΙΗ),1. 23-1. 29 (m, 3Η),1. 67 (d, ΙΗ, J = 9. 6Ηζ),2. 02 (dd, ΙΗ, J =1. 2,16. 2Ηζ),2. 20-2. 79 (m, 8Η),3. 08 (d, ΙΗ, J = 18. 6Ηζ),3. 24 (br, ΙΗ),4. 12-4. 20 (m, 2Η),4. 96 (s,ΙΗ),5. 17 (br, ΙΗ),6. 59 (d, ΙΗ, J = 8.1Hz),6. 72 (d, ΙΗ, J = 8.1Hz),12. 12 (s,ΙΗ)。[1448]元素分析(C23H27NO6 · O. 2Η20)[1449](计算值)C,66. 24 ;H, 6. 62 ;N, 3. 36。[1450](实验值)C, 66. 29 ;H, 6. 50 ;N, 3. 45。[1451](第二个步骤)7-异丙基氨基羰基纳曲酮[1452] 在微波辐照下在180°C下搅拌第一个步骤中得到的7-乙氧基羰基纳曲酮(200mg,0. 484mmol)、异丙胺(O. 412mL, 4. 84mmol)和三乙胺(O. 202mL,1. 45mmol)在 2-甲氧基乙醇 (1. 5mL)中的溶液45分钟。冷却到室温后,向反应混合物中加入7mL的5mol/L盐酸,并在 70°C下继续搅拌20分钟。冷却反应溶液后,用氨水调整pH值到8. 5,然后用乙酸乙酯萃取。 用水洗涤有机层,干燥,并蒸发溶剂。通过硅胶柱色谱法(氯仿:甲醇=99 :1至94 : 6) 纯化残余物得到140mg标题化合物,产率为68%。[1453]匪 R(300MHz,d6_DMS0) δ O. 12-0. 15(m,2H),0· 44-0. 53(m,2H),0· 83 (m, I Η),1. 02 (d, 3Η, J = 6. 6Hz),1. 08 (d, 3Η, J = 6. 6Ηζ),1. 41 (d, ΙΗ, J=Il. 4Ηζ),1. 85 (d, ΙΗ, J =15. 6Ηζ),2. 04-2. 62 (m, 8Η),3. 04 (d, ΙΗ, J = 18. 6Ηζ),3. 24 (m, ΙΗ),3. 96 (m, ΙΗ),4· 71 (S, ΙΗ),4. 74 (s,ΙΗ) ,6. 51 (d, ΙΗ, J = 8. 4 Hz),6. 56 (d, ΙΗ, J = 8. 4Ηζ),7. 40 (br d, ΙΗ, J =7. 2Ηζ),9. 16 (s,ΙΗ),14. 50 (s,ΙΗ)。[1454] 元素分析(CMH3ON2O5 · O. 2Η20)[1455] (计算值)C,67. 02 ;H, 7. 12 ;N, 6· 51。[1456] (实验值)C,67. 02 ;H, 7. 20 ;N, 6. 49。[1457] [实施例2][1458] 化合物(1-44)的制备[1459] [化学式12][1460]
[1461] 其中Bn代表苄基,Me代表甲基,Et代表乙基,Pri代表异丙基。
[1462](第一个步骤)3-0-苄基-7-乙氧基羰基-6-0-甲基纳曲酮
[1463] 向非专利文献2中描述的3-0-节基-7-乙氧基羰基纳曲酮(504mg, I mmol)在四氢呋喃(IOmL)中的溶液中依次加入1,Γ -偶氮二羰基哌啶(379mg,1. 5mmol)、三正丁基膦(370 μ L,1. 5mmol)和甲醇(41 μ I, lmmol),并在室温下搅拌混合物7小时。在减压下浓缩反应溶液,并通过硅胶柱色谱法(己烷/乙酸乙酯)纯化残余物得到标题化合物(421mg,81% ),为无色油。
[1464] 1H NMR (CDCl3, δ ppm) :0· 10-0. 20 (m,2H),O. 50-0. 65 (m,2H),O. 88 (m,1H),1. 26 (t,J = 6. 6Hz,3H),1. 67 (d, J = 11. 4Hz,1H),2. 15-2. 80 (m,8H),3. 00-3. 30 (m,2H),3. 93 (s,3H), 4. 05-4. 20(m,2H),4. 86 (br s’ 1H),5. 15(s,2H),5. 18 (br s’ 1H) ,6. 57 (d, J = 8.1Hz,1H),6. 72 (d, J = 8.1Hz,1H),7. 28-7. 45 (m, 5H)。
[1465](第二个步骤)3-0-苄基-7-异丙基氨基羰基-6-0-甲基纳曲酮
[1466] 向在第一个步骤中得到的3-0-苄基-7-乙氧基羰基-6-0-甲基纳曲酮(145mg,O. 28mmol)在甲醇(6mL)和二氧杂环己烧(2mL)中的混合溶液中加入50%氢氧化钾水溶液(2mL),并在50°C下搅拌混合物30分钟。冷却反应溶液到室温,并用O. 5M柠檬酸水溶液调整到pH = 4. 0,然后用乙酸乙酯萃取。依次用水、盐水盐水洗涤有机层,用无水硫酸钠干燥,并在减压下浓缩。得到的结晶残余物3-0-苄基-7-羧基-6-0-甲基纳曲酮不用纯化就用在下面的反应中。向上述残余物在二甲基甲酰胺(3mL)的溶液中依次加入1-乙基-3-(3-二甲基氨基丙基)碳二亚胺盐酸盐(40mg,0. 2mmol)、1-轻基苯并三唑(27mg,0. 2mmol)和异丙胺(16μ L,0. 182mmol),并在室温下搅拌混合物15小时。将反应溶液倒入到水中,并用乙酸乙酯萃取,用水洗涤有机层,用无水硫酸钠干燥,并在减压下浓缩。通过硅胶柱色谱法(氯仿/甲醇=9/1)纯化残余物得到标题化合物(39mg,44% ),为无色泡沫。
[1467] 1H NMR (CDCl3, δ ppm) :0· 10-0. 20 (m,2H),O. 50-0. 65 (m,2H),O. 88 (m,1H),1. 13 (d,J = 2. lHz,3H),1. 15(d,J =1. 8Hz,3H),1. 58 (d, J = 11. 4Hz,1H),2. 08-2. 80 (m,8H),2. 99-3. 30(m,2H) ,3. 94(s,3H) ,4. 06(m, 1H) ,4. 83 (br s,1H),5. 14 (d,J = 2.4Hz,2H),5. 23 (br s’ 1H) ,6. 56 (d, J = 8. 4Hz, 1H) ,6. 72 (d, J = 8. 4Hz, 1H),7. 28-7. 45 (m, 6H)。
[1468](第三个步骤)7-异丙基氨基羰基-6-0-甲基纳曲酮[1469] 向在第二个步骤中得到的3-0-苄基-7-异丙基氨基羰基-6-0-甲基纳曲酮 (33mg,0. 073mmol)在四氢呋喃(5mL)中的溶液中加入氢氧化钮(33mg),并在氢气气氛下搅拌混合物I小时。用C盐过滤反应溶液,在减压下浓缩滤液。通过硅胶柱色谱法(氯仿/ 甲醇=9/1)纯化残余物得到标题化合物(13mg,41% ),为无色泡沫。[1470] 1H NMR(O)Cl3, δ ppm) :0. 10-0. 15 (m,2H),O. 50-0. 70 (m,2H),O. 85 (m,ΙΗ),1. 12 (d, J = 0. 9Hz,3H),1. 14 (d, J = 0. 9Hz,3H),1. 66 (d, J = 11. 4Hz,1H),2. 06-2. 80 (m,8H), 3. 00-3. 30 (m, 2H),3. 92 (s, 3H),4. 05 (m, 1H),4. 80 (br s,1H),5. 26 (br s,1H),6. 56 (d, J =8.1Hz, 1H) ,6. 69 (d, J = 8.1Hz, 1H),7. 36 (d, J = 7. 8Hz, 1H)。[1471][实施例3][1472][化学式13][1473]
[1474] 其中Bn代表苄基,Me代表甲基,Et代表乙基。[1475](第一个步骤)[1476] 将化合物(I) (28. 7g,57. Ommol)在四氢呋喃(250mL)中的溶液冷却到_10°C,并向溶液中依次加入1,Γ-偶氮二羰基哌啶(21. 6g,85. 5mol)、三正丁基膦(21. 4mL,85. 5mmol) 和苄醇(6. 50mL,62. 7mmol),并在室温下搅拌混合物6小时45分钟。过滤反应溶液并在减压下浓缩滤液,通过硅胶柱色谱法(氯仿一氯仿/甲醇=50/1)纯化残余物以定量得到目标化合物(2) (33. 8g),为浅黄色油。[1477] 1H NMR (CDCl3, δ ppm) :0. 10-0. 20 (m,2H),O. 50-0. 65 (m,2H),O. 88 (m,ΙΗ),O. 94 (t, J = 7. 2Hz,3H),1. 20-3. 60 (m, 11H) ,4. 14 (q, J = 7. 2Hz,2H),5. 10-5. 35 (m, 5H), 6. 58 (d, J =8.1Hz,1H) ,6. 74 (d, J = 8.1Hz,1H),7. 15-7. 50 (m, I OH)[1478](第二个步骤)[1479] 向在第一个步骤中得到的化合物⑵(33. 8g,57. Ommol)在甲醇(130mL)和二氧杂环己烷(43mL)中的混合溶液中加入4N氢氧化钾水溶液(43mL),并在50°C下搅拌混合物14 小时35分钟。冷却反应溶液到室温,并在减压下浓缩,用冰水和2N盐酸调整残余物到pH = 3-4,然后用乙酸乙酯和四氢呋喃的混合溶液萃取。依次用水和盐水洗涤有机层,用无水硫酸钠干燥,并在减压下浓缩。用醚将残余物转化成粉末得到目标化合物(3) (24. Sg, 77%), 为无色粉末。[1480] 1H 匪R(DMS0-d6,δ ppm) :0. 20-0. 40 (m,2H),O. 50-0. 65 (m,2H),O. 95 (m,1H),1. 30-3. 60 (m, 11H) ,5. 00-5. 25 (m,5H),5. 39 (s, 1H) ,6. 68 (d, J = 8.1Hz, 1H) ,6. 88 (d, J = 8.1Hz,1H), 7. 27-7. 52 (m, I OH)[1481](第三个步骤)[1482] 向在第二个步骤中得到的化合物(3) (350mg,0. 619mmol)在四氢呋喃(4mL)中的溶液中依次加入1-乙基-3-(3-二甲基氨基丙基)碳二亚胺盐酸盐(142mg,0. 743mmol)、1-轻基苯并三唑(IOOmg,O. 743mmol)、二甲基甘氨酸甲酯盐酸盐(114mg,O. 743mmol)和 N-甲基吗啉(82yL,0. 743mmol),在室温下搅拌混合物过夜。将反应溶液倒入冰水和饱和碳酸氢钠水溶液内,然后用乙酸乙酯萃取,用盐水洗涤有机层,用无水硫酸钠干燥,并在减压下浓缩。通过硅胶柱色谱法(氯仿/甲醇=50/1)纯化残余物得到目标化合物(4) (300mg,73% ),为浅黄色泡沫。[1483] 1H NMR (CDCl3, δ ppm) :0. 08-0. 20 (m,2H),O. 50-0. 60 (m,2H),O. 87 (m,ΙΗ),1. 13 (s, 3H),1. 22(s,3H),1. 55-2. 80 (m,11H),3. 62(s,3H),4. 85 (br s’ 1H) ,5. 13-5. 40 (m, 5H), 6. 58 (d, J = 8. 4Hz, 1H) ,6. 76 (d, J = 8. 4Hz, 1H),7. 26-7. 48 (m, 10H) ,7. 94 (s,1H)[1484](第四个步骤)[1485] 向在第三个步骤中得到的化合物(4) (290mg,0. 436mmol)在甲醇(4mL)中的溶液中加入氢氧化钯^Omg),然后在氢气气氛下搅拌3小时。用C盐过滤反应溶液,并在减压下浓缩滤液。用己烷/乙酸乙酯结晶残余物得到目标化合物(1-49) (181mg,86% ),为无色晶体。[1486] 1H 匪R(DMS0-d6,δ ppm) :0. 10-0. 20 (m,2H),O. 40-0. 57 (m,2H),O. 84 (m,1H),1. 33(s,3H),1. 37(s,3H),1. 40-3. 40 (m, 11H) ,3. 55(s,3H),4. 72(s, 1H) ,4. 77 (br s, 1H), 6. 52(d, J = 8.1Hz, 1H) ,6. 57(d, J = 8.1Hz, 1H),7. 68 (br s’ 1H) ,9. 18 (br s’ 1H),13. 78 (br s,lH)[1487] 按照相同的过程,可合成其它化合物(I)。下面显示了结构式和物理常数。[1488] 在表中,Me代表甲基,Et代表乙基,Pri代表异丙基,Ph代表苯基。[1489] 另外,在表中,[1490][化学式 14]
[1492][表 9][1493]
[1494][表 10]
[1495]
[1496][表 11][1497]
[1498][表 12]
[1499]
[1500][表 13][1501]
[1502][表 14]
[1503]
[1504][表 15][1505]
[1506] [表 16]
[1507]
[1508][表 17][1509]
[1510][表 18]
[1511]
[1512][表 19][1513]
[1514][表 20]
[1515]
[1516][表 21][1517]
[1518][表 22]
[1519]
[1520][表 23]
[1521]
[1522][表 24]
[1523]
[1524][表 25]
[1525]
[1526][表 26]
[1527]
[1528][表 27]
[1529]
[1532][表 29]
[1533]
[1534][表 30]
[1535]
[1536][表 31]
[1537]
[1538][表 32]
[1539]
[1540][表 33]
[1541]
[1542][表 34]
[1543]
[1544][表 35]
[1545]
[1546][表 36]
[1547]
[1548][表 37]
[1549]
[1550] [表 38]
[1551]
[1552][表 39]
[1553]
[1554][表 40]
[1555]
[1556] [表 41]
[1557]
[1558][表 42]
[1559]
[1560][表 43]
[1561]
[1562][表 44]
[1563]
[1564] [表 45]
[1565]
[1566][表 46]
[1567]
[1568][表 47]
[1569]
[1570][表 48]
[1571]
[1572][表 49]
[1573]
[1574][表 50]
[1575]
[1576][表 51]
[1577]
[1578][表 52]
[1579]
[1580] [表 53]
[1581]
[1582][表 54]
[1583]
[1584][表 55]
[1585]
[1586][表 56]
[1587]
[1588][表 57]
[1589]
[1590] [表 58]
[1591]
[1592][表 59]
[1593]
[1594][表 60]
[1595]
[1596][表 61]
[1597]
[1598] [表 62]
[1599]
[1600] [表 63]
[1601]
[1602][表 64]
[1603]
[1604][表 65]
[1605]
[1606][表 66]
[1607]
[1608][表 67]
[1609]
[1610][表 68]
[1611]
[1612](测量的LC/MS的条件)*1
[1613]柱:ChromoIith Flash ROD RP_18e25 X 4. 6mm1. D.
[1614]流速:2ml/min
[1615] UV 检测器:280nm
[1616]溶剂体系:[A] = H20_0. 05% HCOOH
[1617] [A] = Me0H_0. 05% HCOOH
[1618]梯度:0min :90% [A]_10% [B]
[1619] 0. 2min :90% [A]_10% [B]
[1620]1. Omin :10% [A]_90% [B]
[1621]1. 80min :10% [A]_90% [B][1622] 附带条件,具有符号#的值遵循下面的测量条件
[1623]柱:Phenomenex Luna 5 μ C18 (2) 100A,尺寸 50 X 4. 60mm
[1624]梯度:在 3 分钟期间内 10%-100% Acetnitrile 线性,3. OmL/min
[1625] 试验实施例1阿片样物质δ受体的结合分析
[1626] I)制备用于结合分析的膜样品的方法
[1627] 使用在_80°C下存放的大鼠大脑(Sic :SD)。向已称量的大脑中加入20倍量的冰冷 IOmM Tris-HCl 缓冲液(ρΗ7· O),用 Histocolon (NIT1-ON)均化(25000rpm, 30 秒)混合物,并在36600Xg下离心20分钟。向得到的球粒中加入15ml相同的缓冲液,并类似地用Histocolon处理混合物,并离心。重复这种洗涤工作两次。离心后,向得到的球粒中加入15mL 50mM Tris-HCl缓冲液(pH7. 4),并用Histocolon处理,最后重悬浮在10倍量的相同缓冲液中,使用其作为粗膜部分(Life Sci,48,111-116,1991)。冷冻所制备的膜样品并在_80°C下存放,分析时,快速解冻样品,并用50mM Tris-HCl缓冲液(pH7. 4)稀释到约900 μ g/mL,离心和Histocolon处理后,用于试验。为了测量膜样品的蛋白质浓度,使用Micro BCA蛋白质分析试剂盒(PIERCE)。
[1628] 2) δ受体结合分析和数据分析的方法
[1629] 向以10倍级别稀释的10 μ I试验化合物的溶液中加入10 μ I最终3nM[3H]-DADLE(51. 5Ci/mmol =PerkinElmer)作为配体。将已加入 IOOmM 氯化胆碱、3mMMnCl2和IOOnM DAMGO的480 μ I大鼠大脑膜部分放到管内,并在25°C下培养2小时。培养后,用已用O. 5 %聚乙二亚胺预处理的Whatman GF/C过滤器抽滤,并用2. 5mL冰冷的IOmMTris-HCl缓冲液(pH7. 4)洗涤四次。洗涤后,将过滤器转移到微型小瓶用于液体闪烁计数,加入5mL闪烁物(Cleasol I),使其静置过夜,用液体闪烁计数器Tr1-Carb2200CA (PACKARD)测量放射性三次。使用DMSO用于总结合(总结合:TB)进行数据分析,使用20 μ M左洛啡烷用于非特异性结合(非特异性结合:ΝΒ),使用通过Scatchard曲线分析预先得到的KD值(2. 93ηΜ)计算试验化合物的Ki值。
[1630] 结果显示在表69中。
[1631][表 69]
[1632]
[1633] 从上面结果可看出,化合物(I)具有对阿片样物质δ受体的亲合性。试验实施例2对阿片样物质μ受体的结合分析
[1634] I)制备用于结合分析的膜样品的方法
[1635] 使用在_80°C下存放的大鼠大脑(Sic :SD)。向已称量的大脑中加入20倍量的冰冷 IOmM Tris-HCl 缓冲液(pH 7. O),用 Histocolon (NIT1-ON)均化(25000rpm, 30 秒)混合物,并在36600Xg下离心20分钟。向得到的球粒中加入15ml相同的缓冲液,并类似地用Histocolon处理混合物,并离心。重复这种洗涤工作两次。离心后,向得到的球粒中加入15mL 50mM Tris-HCl缓冲液(pH7. 4),并用Histocolon处理,最后重悬浮在10倍量的相同缓冲液中,使用其作为粗膜部分(Life Sci,48,111-116,1991)。冷冻所制备的膜样品并在_80°C下存放,试验时,快速解冻样品,并用50mM Tris-HCl缓冲液(pH7. 4)稀释到约900 μ g/mL,离心和Histocolon处理后,用于试验。为了测量膜样品的蛋白质浓度,使用Micro BCA蛋白质分析试剂盒(PIERCE)。
[1636] 2) μ受体结合分析和数据分析的方法
[1637] 向以10倍级别稀释的10 μ I试验化合物的溶液中加入10 μ I最终2nM[3H]-DAMGO(51. 5Ci/mmol =PerkinElmer)作为配体,另外,将480 μ I大鼠大脑膜部分放到管内,并在25°C下培养2小时。培养后,用已用O. 5%聚乙二亚胺预处理的Whatman GF/C过滤器抽滤,并用2. 5mL冰冷的IOmM Tris-HCl缓冲液(pH7. 4)洗涤四次。洗涤后,将过滤器转移到微型小瓶用于液体闪烁计数,加入5mL闪烁物(Cleasol I),使其静置过夜,用液体闪烁计数器Tr1-Carb 2200CA (PACKARD)测量放射性三次。使用DMSO用于总结合(总结合:TB)进行数据分析,使用20 μ M左洛啡烷用于非特异性结合(非特异性结合:ΝΒ),使用通过Scatchard 曲线分析(Anal. Biochem. 107 (I),220-239,1980)预先得到的 KD 值(1. 72nM)计算试验化合物的Ki值。
[1638] 结果显示在表70中。
[1639][表 70]
[1640]
试
[1641] [1641]试验实施例3小鼠碳粉转运分析
[1642] I)试验饮食(碳粉)的制备
[1643] 使用10«7^%阿拉伯胶水溶液,制备5w/v%活性碳溶液,使用其作为试验饮食。
[1644] 2)动物
[1645] 使用ddY系雄性小鼠(5-6周龄)。在分析开始前使小鼠禁食约20或更多个小时,并随意地给予水。
[1646] 3)试验化合物和介质
[1647] 将试验化合物溶解在溶剂(DMAA/Solutol/5%甲基葡胺=15/15/70)中。
[1648] DMAA :N,N-二甲基乙酰胺
[1649] Solutol :Solutol (注册商标)HS15
[1650] 甲基葡胺:D(-)_N-甲基葡糖胺
[1651] 将盐酸吗啉溶解在生理盐水中。试验化合物、上述溶剂和吗啉都以10mL/kg的液
体量给药。
[1652] 4)分析方法
[1653] 皮下给药试验化合物3mg/kg (试验化合物给药组)或溶剂(溶剂给药组),15分钟后,对所有组给药3mg/kg量的吗啉。作为对照组,皮下给药溶剂,并在15分钟后给药生理药水。
[1654] 在给药吗啉后15分钟时口服给药试验饮食10mL/kg。在试验饮食给药后30分钟时(在试验物质给药后60分钟时),从食道到靠近胃贲门部位的回肠盲肠部位分离所有小鼠。测量从胃幽门部位到回肠盲肠部位的距离(小肠的完整长度)和直到碳粉到达前端部位的距离(碳粉移动距离)。使用下面的方程计算吗啉对碳粉转运抑制活性的拮抗活性,表示为MPE (%)。结果显示在表71中。
[1655] 转运率(%)=(碳粉移动距离)/小肠的完整长度(cm)) X 100
[1656] MP. E. (%) = {(试验化合物给药组每个个体的小肠转运率(% )-溶剂给药组的平均小肠转运率))/(对照组的平均小肠转运率)-溶剂给药组的平均小肠转运率
(% ))} XlOO
[1657][表 71]
[1658]
[1659] 制剂实施例1
[1660] 制备包含以下成分的颗粒。
[1661] 成分用式⑴表示的化合物 IOmg
[1662] 乳糖 700mg
[1663] 玉米淀粉 274mg
[1664] HPC-L 16mg
[1665] IOOOmg
[1666] 将用式⑴表示的化合物和乳糖通过60目筛。使玉米淀粉通过120目筛。用V-型混合器混合它们。向混合粉末中加HPC-L(低粘度羟丙基纤维素)水溶液,捏合材料,造粒
(挤出造粒,孔直径O. 5-1_),并干燥。使用振动筛(12/60目)使得到的干颗粒通过筛以得到颗粒。
[1667] 制剂实施例2
[1668] 制备包含以下成分的用于填充到胶囊内的颗粒。
[1669] 成分用式⑴表示的化合物 15mg
[1670] 乳糖 90mg
[1671] 玉米淀粉 42mg
[1672] HPC-L 3mg[1673] 150mg
[1674] 将用式(I)表示的化合物和乳糖通过60目筛。使玉米淀粉通过120目筛。混合它们,向混合粉末中加入HPC-L溶液,捏合材料,造粒,并干燥。得到的干颗粒为尺寸调整过的,将这150mg装入4号硬明胶胶囊内。
[1675] 制剂实施例3
[1676] 制备包含以下成分的片剂。
[1677] 成分用式⑴表示的化合物 IOmg
[1678] 乳糖 90mg
[1679] 微晶纤维素 30mg
[1680] CMC-Na 15mg
[1681] 硬脂酸镁 5mg
[1682] 150mg
[1683] 使式⑴表示的化合物、乳糖、微晶纤维素、CMC-NA(羧甲基纤维素钠盐)通过60目筛,并混合。向混合的粉末中混入硬脂酸镁得到用于制片剂的混合粉末。将该混合粉末压缩得到150mg片剂。
[1684] 制剂实施例4
[1685] 加热以下成分,混合,并杀菌得到注射剂。
[1686] 成分用式⑴表示的化合物 3mg
[1687] 非离子表面活性剂 15mg
[1688] 注射用纯化水 Iml
[1689][工业实用性]
[1690] 本发明能用作减轻副作用如发呕、呕吐和/或便秘的药剂。
Claims (12)
1.用式(I)表示的化合物或其药物可接受的盐: [化学式I] 其中R1为氢、Cl-Cio烷基; R2为: Cl-ClO烷基,任选由以下取代=Cl-ClO烷氧基、C1-10烷氧基羰基、芳基、芳氧基、任选由Cl-ClO烷基或芳基取代的杂环基,其中该芳基是苯基或萘基,其中该芳氧基是苯氧基或萘氧基,和其中该杂环基是异》恶唑基、〃恶唑基或》恶二唑基, C3-C10环烷基,任选由以下取代=Cl-ClO烷氧基Cl-ClO烷基或Cl-ClO烷氧基羰基,芳基,其任选由以下取代:卤素、Cl-Cio烷基、Cl-ClO烷氧基、Cl-ClO烷基氨基、羧基、Cl-ClO烷基氨基甲酰基或Cl-ClO烷基氨磺酰基,且其中该芳基是苯基或萘基, 杂环基,其任选由以下取代=Cl-Cio烷基、Cl-ClO烷氧基、氧代或羟基,且其中该杂环基是吡唑基、吡啶基、嘧啶基、噻吩基、喹啉基、四氢呋喃基、或异恶I唑基; 芳基磺酰基,其任选由卤素或Cl-Cio烷氧基取代,其中该芳基磺酰基是苯基磺酰基或萘基磺酰基;或 R1和R2与它们连接的氮原子一起形成吡咯烷环; R3为羟基、任选被芳基磺酰基取代的氨基,其中该芳基磺酰基任选被卤素取代,其中所述芳基磺酰基是苯基磺酰基或萘基磺酰基; R4为氢; R5为C3-C10环烷基Cl-ClO烷基。
2.根据权利要求1的化合物或其药物可接受的盐,其中R3为羟基。
3.根据权利要求1的化合物或其药物可接受的盐,其中R3为任选被芳基磺酰基取代的氨基,其中该芳基磺酰基任选被齒素取代,其中所述芳基磺酰基是苯基磺酰基或萘基磺酰基。
4.根据权利要求1-3中任一项的化合物或其药物可接受的盐,其中 R1为氢或Cl-ClO烷基, R2为: Cl-ClO烷基,任选由以下取代=Cl-ClO烷氧基、C1-10烷氧基羰基、芳基、芳氧基、任选由Cl-ClO烷基或芳基取代的杂环基,其中该芳基是苯基或萘基,和其中该芳氧基是苯氧基或萘氧基,和其中该杂环基是异Ifv唑基、”恶唑基或〃恶二唑基; 苯基,其任选由以下取代:卤素、Cl-Cio烷基、Cl-ClO烷氧基、Cl-ClO烷基氨基、羧基、Cl-Cio烷基氨基甲酰基或Cl-ClO烷基氨磺酰基; C3-C10环烷基,任选由以下取代=Cl-ClO烷氧基Cl-ClO烷基或Cl-ClO烷氧基羰基;或杂环基,其任选由以下取代=Cl-Cio烷基、Cl-ClO烷氧基、氧代或羟基,且其中该杂环基是吡唑基、吡啶基、嘧啶基、噻吩基、喹啉基、四氢呋喃基或异恶唑基;以及R5为环丙基甲基。
5.根据权利要求1-3中任何一项的化合物或其药物可接受的盐,其中 R1为氢, R2为: 未被取代的Cl-ClO烷基; 被杂环基取代的Cl-ClO烷基,该杂环基任选被芳基取代,其中该杂环基是异P恶唑基、〃恶唑基或〃恶二唑基,其中该芳基是苯基或萘基; 被Cl-ClO烷氧基取代的Cl-ClO烷基; 未被取代的苯基; 被Cl-ClO烷基取代的苯基; 被Cl-ClO烷氧基取代的苯基; 被Cl-ClO烷氧基羰基取代的C3-C10环烷基; 被Cl-ClO烷氧基取代的杂环基,其中该杂环基是吡唑基、吡啶基、嘧啶基、噻吩基、喹啉基、四氢呋喃基或异恶唑基; 或 R3为羟基, R4为氢,和 R5为环丙基甲基。
8. —种药物组合物,其包含根据权利要求1-7中任一项的化合物或其药物可接受的盐。
9.根据权利要求1-7中任一项的化合物或其药物可接受的盐用来制备具有阿片样物质受体拮抗活性的组合物的用途。
10.权利要求1-7中任一项的化合物或其药物可接受的盐用来制备用于减轻和/或预防由具有阿片样物质受体激动活性的化合物弓I起的副作用的组合物的用途。
11.根据权利要求10的用途,其中所述副作用为发呕、呕吐和/或便秘。
12.根据权利要求10或11的用途,其中具有阿片样物质受体激动活性的化合物为吗啡、羟考酮或其药物可接受的盐。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005151864 | 2005-05-25 | ||
JP151864/2005 | 2005-05-25 | ||
JP2006065762 | 2006-03-10 | ||
JP065762/2006 | 2006-03-10 | ||
JPPCT/JP2006/310231 | 2006-05-23 | ||
PCT/JP2006/310231 WO2006126529A1 (ja) | 2005-05-25 | 2006-05-23 | 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体 |
PCT/JP2006/310454 WO2006126637A1 (ja) | 2005-05-25 | 2006-05-25 | 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101228172A CN101228172A (zh) | 2008-07-23 |
CN101228172B true CN101228172B (zh) | 2013-04-03 |
Family
ID=37451954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800271187A Active CN101228172B (zh) | 2005-05-25 | 2006-05-25 | 6,7-不饱和-7-氨基甲酰基取代的吗啡喃衍生物 |
Country Status (18)
Country | Link |
---|---|
US (4) | US8084460B2 (zh) |
EP (1) | EP1889848B8 (zh) |
JP (1) | JP4323547B2 (zh) |
KR (1) | KR100912782B1 (zh) |
CN (1) | CN101228172B (zh) |
AU (1) | AU2006250390B2 (zh) |
BR (1) | BRPI0610343B8 (zh) |
CA (1) | CA2609733C (zh) |
DK (1) | DK1889848T3 (zh) |
ES (1) | ES2525215T3 (zh) |
HU (1) | HUS1900034I1 (zh) |
MX (1) | MX2007014588A (zh) |
NL (1) | NL300996I2 (zh) |
PL (1) | PL1889848T3 (zh) |
PT (1) | PT1889848E (zh) |
RU (1) | RU2403255C2 (zh) |
TW (1) | TWI311056B (zh) |
WO (2) | WO2006126529A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006126529A1 (ja) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体 |
US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
EP2240022B1 (en) * | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
JP5252391B2 (ja) * | 2008-02-21 | 2013-07-31 | 学校法人北里研究所 | オキサビシクロ[2.2.2]オクタンを有するモルヒナン誘導体およびその医薬用途 |
WO2010033195A1 (en) * | 2008-09-16 | 2010-03-25 | Nektar Therapeutics | Pegylated opioids with low potential for abuse |
TW201118084A (en) * | 2009-09-18 | 2011-06-01 | Adolor Corp | The use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders |
WO2011142620A2 (en) * | 2010-05-13 | 2011-11-17 | Green Cross Corporation | (+)-3-hydroxymorphinan-based polycycle derivatives as neuroprotectants |
MX338392B (es) * | 2010-11-12 | 2016-04-13 | Shionogi & Co | Cristal de derivado de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo. |
EP2851075B1 (en) * | 2012-05-14 | 2021-12-01 | Shionogi & Co., Ltd. | Preparation containing 6,7-unsaturated-7-carbamoylmorphinan derivative |
EP3560487A4 (en) * | 2016-12-26 | 2020-07-29 | Shionogi & Co., Ltd. | PRODUCTION METHOD FOR FORMULATION WITH IMPROVED UNIFORMITY OF CONTENT |
EP3773573A4 (en) | 2018-04-12 | 2022-04-06 | Morphic Therapeutic, Inc. | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4) (BETA7) |
KR102201609B1 (ko) | 2019-04-19 | 2021-01-12 | 연성정밀화학(주) | 날데메딘의 제조방법 |
WO2021076890A1 (en) | 2019-10-16 | 2021-04-22 | Morphic Therapeutic, Inc. | INHIBITING HUMAN INTEGRIN α4β7 |
WO2021100728A1 (ja) | 2019-11-20 | 2021-05-27 | 塩野義製薬株式会社 | 6,7-不飽和-7-カルバモイルモルヒナン誘導体含有固形製剤 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4272541A (en) | 1978-06-02 | 1981-06-09 | Miles Laboratories, Inc. | 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them |
US4275205A (en) * | 1980-05-05 | 1981-06-23 | Miles Laboratories, Inc. | 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols |
US4347361A (en) * | 1980-12-10 | 1982-08-31 | Sisa, Incorporated | 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds |
US4370333A (en) | 1981-06-29 | 1983-01-25 | Sisa, Incorporated | 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it |
US4443605A (en) | 1982-07-30 | 1984-04-17 | Miles Laboratories, Inc. | 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans |
US4440932A (en) * | 1982-09-09 | 1984-04-03 | Miles Laboratories, Inc. | 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans |
AU686203B2 (en) | 1993-07-23 | 1998-02-05 | Toray Industries, Inc. | Morphinan derivative and medicinal use |
US5464841A (en) | 1993-11-08 | 1995-11-07 | Univ Minnesota | Use of delta opioid receptor antagonists to treat immunoregulatory disorders |
AR005423A1 (es) | 1996-01-10 | 1999-06-23 | Smithkline Beecham Spa | Derivados morfinoides condensados con heterociclos (ii), su uso como sustancia terapeutica y para preparar medicamentos, composiciones farmaceuticasque los contienen y procedimiento para preparar dichos derivados. |
AU5891600A (en) | 1999-07-01 | 2001-01-22 | Chemrx Advanced Technologies, Inc. | Process for synthesizing oxadiazoles |
WO2001037785A2 (en) * | 1999-11-29 | 2001-05-31 | Adolor Corporation | Novel methods and compositions involving opioids and antagonists thereof |
AU5945801A (en) | 2000-05-05 | 2001-11-20 | Pain Therapeutics Inc | Opoid antagonist compositions and dosage forms |
EP1280529A2 (en) | 2000-05-05 | 2003-02-05 | Pain Therapeutics, Inc. | Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists |
US20040024004A1 (en) | 2001-05-04 | 2004-02-05 | Sherman Barry M. | Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists |
WO2002036573A2 (en) * | 2000-10-31 | 2002-05-10 | Rensselaer Polytechnic Institute | 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents |
US6770654B2 (en) * | 2000-11-22 | 2004-08-03 | Toray Industries, Inc. | Indole derivatives and use thereof in medicines |
DE10161963A1 (de) * | 2001-12-17 | 2003-07-03 | Johannes Schuetz | 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung |
DE10229842A1 (de) * | 2002-07-03 | 2004-02-05 | Helmut Prof. Dr. Schmidhammer | Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung |
KR20050025347A (ko) * | 2002-07-11 | 2005-03-14 | 도레이 가부시끼가이샤 | 오심/구토의 치료 또는 예방제 |
EP1539767A4 (en) * | 2002-09-18 | 2006-07-19 | Univ Missouri | FOR THE DELTA OPIOID RECEPTOR SELECTIVE OPIATANALOGA |
US20040157784A1 (en) | 2003-02-10 | 2004-08-12 | Jame Fine Chemicals, Inc. | Opiod tannate compositions |
WO2005105093A2 (en) | 2003-08-26 | 2005-11-10 | Duke University | METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION |
DK1758452T3 (en) | 2004-05-28 | 2017-05-01 | Human Biomolecular Res Inst | METABOLIC STABLE ANALGETICS AND Painkillers |
US20060063792A1 (en) | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
US7142420B2 (en) | 2004-09-20 | 2006-11-28 | Qualcomm, Incorporated | Devices and methods for controlling relative movement between layers of an electronic device |
WO2006126529A1 (ja) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | 6,7-不飽和-7-カルバモイル置換モルヒナン誘導体 |
MX338392B (es) | 2010-11-12 | 2016-04-13 | Shionogi & Co | Cristal de derivado de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo. |
-
2006
- 2006-05-23 WO PCT/JP2006/310231 patent/WO2006126529A1/ja active Application Filing
- 2006-05-24 TW TW095118443A patent/TWI311056B/zh active
- 2006-05-25 BR BRPI0610343A patent/BRPI0610343B8/pt active IP Right Grant
- 2006-05-25 MX MX2007014588A patent/MX2007014588A/es active IP Right Grant
- 2006-05-25 CA CA2609733A patent/CA2609733C/en active Active
- 2006-05-25 US US11/920,851 patent/US8084460B2/en not_active Ceased
- 2006-05-25 US US15/064,511 patent/USRE46365E1/en active Active
- 2006-05-25 PL PL06746833T patent/PL1889848T3/pl unknown
- 2006-05-25 EP EP06746833.0A patent/EP1889848B8/en active Active
- 2006-05-25 AU AU2006250390A patent/AU2006250390B2/en active Active
- 2006-05-25 RU RU2007148412/04A patent/RU2403255C2/ru active
- 2006-05-25 ES ES06746833.0T patent/ES2525215T3/es active Active
- 2006-05-25 JP JP2007517895A patent/JP4323547B2/ja active Active
- 2006-05-25 PT PT67468330T patent/PT1889848E/pt unknown
- 2006-05-25 DK DK06746833.0T patent/DK1889848T3/en active
- 2006-05-25 WO PCT/JP2006/310454 patent/WO2006126637A1/ja active Application Filing
- 2006-05-25 CN CN2006800271187A patent/CN101228172B/zh active Active
-
2007
- 2007-11-23 KR KR1020077027287A patent/KR100912782B1/ko active IP Right Grant
-
2011
- 2011-11-30 US US13/308,483 patent/US8536192B2/en not_active Ceased
-
2016
- 2016-03-08 US US15/064,538 patent/USRE46375E1/en active Active
-
2019
- 2019-06-26 NL NL300996C patent/NL300996I2/nl unknown
- 2019-07-03 HU HUS1900034C patent/HUS1900034I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101228172B (zh) | 6,7-不饱和-7-氨基甲酰基取代的吗啡喃衍生物 | |
EP3774791B1 (en) | Heterocyclic compounds as immunomodulators | |
CN109563075B (zh) | Tlr7/8拮抗剂及其用途 | |
CN101687827A (zh) | 环状基团取代的氨基二氢噻嗪衍生物 | |
CN102448958A (zh) | 嘧啶基和1,3,5-三嗪基苯并咪唑磺酰胺和其在癌症治疗中的用途 | |
EA020511B1 (ru) | Конформационно ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с | |
CN108290871A (zh) | 具有抗癌活性的mdm2-p53相互作用的异吲哚啉酮抑制剂 | |
WO2007039563A1 (en) | 9-azabicyclo [3 . 3 . 1] nonane derivatives as monoamine reuptake inhibitors | |
CN106103450A (zh) | 作为磷酸肌醇3‑激酶抑制剂的三环杂环化合物 | |
CN107848974A (zh) | 芳族磺酰胺衍生物 | |
CN108349988A (zh) | 作为磷酸肌醇3-激酶抑制剂的三环杂环化合物 | |
WO1995001178A1 (fr) | Antitussif | |
TWI723511B (zh) | 一種高活性sting蛋白激動劑化合物 | |
CA3012031A1 (en) | New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors | |
JP2002510685A (ja) | 性腺刺激ホルモン放出ホルモン拮抗薬 | |
ES2585653T3 (es) | Antagonistas del receptor de FSH | |
JP2002539124A (ja) | 性腺刺激ホルモン放出ホルモン拮抗薬としての6−アザインドール化合物 | |
JP2002538205A (ja) | 性腺刺激ホルモン放出ホルモン拮抗薬としての6−アザインドール化合物 | |
CN106831614B (zh) | 取代的苯并二氮杂环类化合物及其制备方法和用途 | |
CN105121405A (zh) | 二羧酸化合物 | |
EP1342723B1 (en) | Indole derivatives and use thereof in medicines | |
JP2002538206A (ja) | 性腺刺激ホルモン放出ホルモン拮抗薬としての6−アザインドール化合物 | |
TWI700281B (zh) | 苯並氮雜䓬衍生物、其製備方法及其在醫藥上的應用 | |
WO2006064779A1 (ja) | 6’位にカルボキシを有するインドロモルヒナン誘導体 | |
CN101119728A (zh) | 6’位上具有羧基的吲哚并吗啡喃衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |